Original Article
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
N Engl J Med 2005; 352:1071-1080March 17, 2005
- Abstract
Background
Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern.
Methods
We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas. All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme.
Results
For all patients except those who died, 2.8 to 3.1 years of follow-up data were available. A composite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the placebo group (1.0 percent), as compared with 16 of 685 patients receiving 200 mg of celecoxib twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence interval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib twice daily (3.4 percent; hazard ratio, 3.4; 95 percent confidence interval, 1.4 to 7.8). Similar trends were observed for other composite end points. On the basis of these observations, the data and safety monitoring board recommended early discontinuation of the study drug.
Conclusions
Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure. In light of recent reports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Risk of the Composite End Point of Death from Cardiovascular Causes, Myocardial Infarction, Stroke, or Heart Failure among Patients Who Received Celecoxib (200 mg Twice Daily or 400 mg Twice Daily) or Placebo.Table 1
Baseline Characteristics of the Patients.Article Activity
- Article
The promise of a lower incidence of gastrointestinal side effects with the use of selective cyclooxygenase-2 (COX-2) inhibitors than with the use of nonselective nonsteroidal antiinflammatory drugs (NSAIDs) or aspirin has led to a marked increase in prescriptions for COX-2 inhibitors, despite the fact that they offer similar degrees of pain relief.1-3 In addition, the identification of COX-2 as a promoter of intestinal tumorigenesis suggested that inhibiting this enzyme could prevent the formation of premalignant colorectal adenomas.4-8 Recently, however, this class of drugs has come under scrutiny because of clinical reports that they were associated with an increased risk of serious cardiovascular harm.9-11 The mechanism of this effect is suggested in part by evidence that selective inhibition of COX-2 can block the production of prostacyclin without affecting the synthesis of thromboxane A2,10 thereby potentially creating a prothrombotic state.
The observation of an increased incidence of death from cardiovascular causes, myocardial infarction, or stroke among patients receiving rofecoxib in the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial and the associated voluntary withdrawal of this drug from the market prompted the data and safety monitoring board and steering committee of a similar ongoing trial of celecoxib to request a focused reassessment of data on cardiovascular safety by an independent committee, with the results presented at their scheduled meeting on December 10, 2004. The study was a prospective, randomized, double-blind, multicenter trial assessing the efficacy of celecoxib for the prevention of adenomatous polyps in patients who had undergone endoscopic polypectomy. Because neither prior clinical trials nor observational studies had reported a clearly increased risk of cardiovascular events with celecoxib use,2,5,12-16 this longer-term, placebo-controlled trial provided an important opportunity to evaluate the potential association. This report describes the findings of the independent cardiovascular safety committee.
Methods
Patients
The Adenoma Prevention with Celecoxib (APC) study compared the efficacy and safety of 200 mg of celecoxib twice daily, 400 mg of celecoxib twice daily, and placebo in reducing the occurrence of adenomatous polyps in the colon and rectum one year and three years after endoscopic polypectomy. The trial was led by the Strang Cancer Prevention Center (New York) and cosponsored by the National Cancer Institute and Pfizer. Ninety-one sites participated (72 in the United States, 1 in the United Kingdom, 8 in Australia, and 10 in Canada). Participants ranged from 32 to 88 years of age and were considered to have a clinically significant risk of colorectal adenoma on the basis of a history of either multiple adenomas or a single adenoma that was at least 0.5 cm in diameter. All known adenomas were removed colonoscopically before drug treatment began.
A detailed medical history, including baseline assessment of cardiovascular disease status and risk factors for cardiovascular disease, was obtained for each patient. The protocol was reviewed and approved by the appropriate institutional review boards, and all patients provided written informed consent before enrollment. Patients were randomly assigned to treatment with the use of a computer-generated randomization schedule. At the time of data review, 2035 patients had undergone randomization in a double-blind manner at a 1:1:1 ratio, after stratification according to the use or nonuse of aspirin for cardiovascular prophylaxis and the enrolling center. Enrollment began in November 1999 and concluded in March 2002. Compliance was assessed by means of both pill counts and standard monitoring of medical records every 6 to 12 weeks.
Review of Cardiovascular Safety
The cardiovascular safety committee developed end-point definitions as guidelines for adjudication. The committee classified and adjudicated the end points by defining a hierarchy of composite end points (based on clinical importance and the prior findings with rofecoxib). These guidelines were designed specifically to assess cardiovascular safety (listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org). An initial review identified all deaths and potential nonfatal cardiovascular adverse events. Two experienced independent assessors reviewed these events using medical records and narratives supplied by site investigators. Myocardial infarction was defined on the basis of either a clinical presentation characterized by typical symptoms, signs, or electrocardiographic changes associated with an elevation in the level of a cardiac marker or angiographic evidence of coronary thrombosis. Stroke was defined as a persistent focal neurologic event whose onset was sudden and was not due to trauma or a tumor. Other cardiovascular events were categorized according to a preplanned schema. When this initial documentation was insufficient for adjudication, additional information was obtained from the investigative sites.
The entire cardiovascular safety committee was unaware of the patients' treatment assignments throughout the review process. For the purposes of this analysis, we evaluated a hierarchy of composite end points, including death from cardiovascular causes, myocardial infarction, stroke, heart failure, unstable angina, and the need for a cardiovascular procedure.
Statistical Analysis
Randomization codes were provided to Statistics Collaborative (Washington, D.C.). All analyses were performed according to the intention-to-treat principle, with data on each patient analyzed according to the original randomized treatment assignment. Log-rank tests were used to compare the time to a cardiovascular event in the three groups for each composite end point of interest. Cox models, with the treatment group as the only covariate, were used to estimate hazard ratios for the two celecoxib groups as compared with the placebo group. Although the randomization was stratified according to the baseline use or nonuse of aspirin and the center, the Cox models did not include these stratifying variables. Censoring was defined by assuming that a patient was followed for 37 months, until death, or until January 6, 2005 (the date defined for this analysis as the common close-out date) — whichever came first. At the time of this review, we had follow-up information for more than 97 percent of the patient-years at risk. Incidence rates were calculated for individual and composite cardiovascular events by dividing the number of patients with events by the number of patient-years at risk.
Important subgroups based on baseline characteristics were prespecified. To examine whether the effect of celecoxib varied between subgroups, we constructed Cox models with terms for treatment, subgroup, and the interaction between subgroup and treatment and evaluated the interaction terms for statistical significance.
Recommendations to the study's data and safety monitoring board were made on the basis of data available at the time of the original analysis. This analysis contains data on three additional cardiovascular events that were not included in the original report.
Results
At the time of the analysis, 77 percent of the 2035 patients had completed the study, and all of the remaining surviving patients had completed at least 2.8 years of follow-up (range, 2.8 to 3.1). The baseline characteristics were similar among the three groups (Table 1Table 1
Baseline Characteristics of the Patients.). The incidence of the prespecified composite cardiovascular end points, analyzed according to the time to the first event, and the associated hazard ratios are shown in Table 2Table 2
Incidence of and Hazard Ratios for the Composite End Points in the Celecoxib Groups Relative to the Placebo Group.. As compared with the placebo group, the group given 200 mg of celecoxib twice daily had a hazard ratio for death from cardiovascular causes, myocardial infarction, stroke, or heart failure of 2.3 (95 percent confidence interval, 0.9 to 5.5), and the group receiving 400 mg of celecoxib twice daily had a hazard ratio of 3.4 (95 percent confidence interval, 1.4 to 7.8). The results for the individual components of the composite end point are shown in Table 3Table 3
Incidence of Individual Cardiovascular and Fatal Events..There were six deaths in the placebo group, six in the group given 200 mg of celecoxib twice daily, and nine in the group given 400 mg twice daily, and one, three, and six of the deaths, respectively, were due to cardiovascular causes. The Kaplan–Meier curves for the combined end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure in the three groups are shown in Figure 1Figure 1
Kaplan–Meier Estimates of the Risk of the Composite End Point of Death from Cardiovascular Causes, Myocardial Infarction, Stroke, or Heart Failure among Patients Who Received Celecoxib (200 mg Twice Daily or 400 mg Twice Daily) or Placebo.. The annualized incidence of death from cardiovascular causes, stroke, myocardial infarction, or heart failure was 3.4 events per 1000 patient-years in the placebo group, 7.8 events per 1000 patient-years in the group given 200 mg of celecoxib twice daily, and 11.4 events per 1000 patient-years in the group given 400 mg twice daily.In addition to the increased risk of the prespecified composite end point of cardiovascular events, the point estimate of the number of venous thromboembolic events was also increased (though not significantly) among patients receiving celecoxib: four in the group given 400 mg of celecoxib twice daily and three in the group given 200 mg twice daily, as compared with one in the placebo group (hazard ratio for the two celecoxib groups combined, 3.5; 95 percent confidence interval, 0.4 to 28.5). There was no apparent increase in the risk of unstable angina, arrhythmia, or the need for a cardiovascular procedure. The hazard ratios associated with celecoxib use decreased when a broader class of cardiovascular events, including unstable angina and the need for a cardiovascular procedure, was added to the composite end point. The hazard ratio associated with celecoxib was not significantly affected by any of the baseline characteristics examined, including aspirin use at baseline (Table 4Table 4
Incidence of Death from Cardiovascular Causes, Myocardial Infarction, Stroke, or Heart Failure According to Baseline Characteristics.).On December 16, 2004, on the basis of these findings, the advice of the cardiovascular safety committee, and previous findings with drugs in the same class, the data and safety monitoring board concluded that continued exposure to celecoxib placed patients at increased risk for serious cardiovascular events. On the basis of this recommendation, the steering committee stopped the use of study medication among the patients remaining in the trial. The trial remained blinded, and follow-up for the end point of adenoma continued. Three events that were documented after the study was stopped are included in the present analysis; their inclusion does not alter the overall conclusions of the report issued on December 16, 2004.
Discussion
In a large, randomized, placebo-controlled, double-blind, multicenter trial, we found that twice-daily treatment with 200 or 400 mg of celecoxib to prevent colorectal adenomas led to a dose-related increase in the risk of serious cardiovascular events, including death from cardiovascular causes, myocardial infarction, stroke, and heart failure. These results were consistent among the individual components of the composite end point. Because the use of other selective COX-2 inhibitors, including rofecoxib, valdecoxib, and parecoxib, has also been associated with an increased rate of cardiovascular events,17,18 our results heighten concern that this class of drug may be associated with increased cardiovascular risk. The cardiovascular safety committee also completed a preliminary review of cardiovascular safety in another study, the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial, which randomly assigned patients with a history of colorectal adenomas to receive either 400 mg of celecoxib once a day or placebo. The preliminary analysis did not show an increase in risk at this dose.
The reason for the apparent increase in cardiovascular risk associated with the use of COX-2 inhibitors is uncertain. One prominent hypothesis involves the effects of COX-2 inhibitors on two key prostanoids, prostacyclin and thromboxane A2, which have a crucial role in vascular homeostasis.9,19,20 These prostanoids are generated by the action of the cyclooxygenase-1 (COX-1) and COX-2 isoenzymes on arachidonic acid.21 Thromboxane A2, which promotes platelet aggregation, vasoconstriction, and smooth-muscle proliferation, is synthesized primarily in platelets, which express only COX-1. Conversely, prostacyclin, which has antiaggregative, antiproliferative, and vasodilatory actions, is the main prostanoid product of endothelial cells, synthesized as a result of the action of COX-2.22
Whereas nonselective NSAIDs inhibit both COX-1 and COX-2, selective COX-2 inhibitors act primarily on COX-2.9 The selective COX-2 inhibitors may therefore suppress vascular production of prostacyclin without affecting the synthesis of platelet-derived thromboxane A2. This imbalance may promote thrombosis and increase the risk of cardiovascular events.10 Nonaspirin, nonselective NSAIDs may also not sufficiently reduce thromboxane A2 synthesis long enough to prevent platelet aggregation and atherosclerotic events.10 Other potentially detrimental effects of COX-2 inhibitors have been suggested, including elevated blood pressure, though some reports have indicated that these drugs may have beneficial effects on vascular health.23
In contrast to our findings, most of the earlier clinical trials of selective COX-2 inhibitors in patients with arthritis did not appear to show an increase in cardiovascular risk.2,5,14,24 These trials, however, were generally short-term studies designed to assess the use of this class of drug for pain relief and to evaluate associated adverse gastrointestinal events. They included a relatively small proportion of patients at high risk for cardiovascular events or excluded such patients, despite the fact that many patients who are taking these drugs or who are considered candidates for this therapy are at high cardiovascular risk.25 Consequently, the studies lacked adequate statistical power to confirm or refute a cardiovascular hazard related to the use of COX-2 inhibitors.11 The use of active rather than placebo controls in many of these studies also made the findings difficult to interpret.
The results of the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial3 and a subsequent study, APPROVe,26 raised questions about the safety of rofecoxib. The VIGOR trial, which compared a nine-month course of 50 mg of rofecoxib per day (a larger dose than that usually recommended for the long-term treatment of arthritis) with naproxen in patients with rheumatoid arthritis, reported a higher risk of myocardial infarction among the patients receiving rofecoxib.27 Some have attributed these findings to the potentially cardioprotective effects of naproxen,28,29 although this interpretation has been a source of contention.18,20
More recently, the APPROVe trial, a randomized, placebo-controlled trial designed to evaluate the efficacy of rofecoxib for preventing colorectal polyps in patients with a history of colorectal adenomas, was terminated early because of an increased risk of cardiovascular events.10,26 These results prompted voluntary withdrawal of rofecoxib from the market. Topol reported that another controlled trial also showed an increased risk of cardiovascular events with treatment with 12.5 mg of rofecoxib per day, as compared with nabumetone or placebo.30
The results of other studies have aroused concern about the safety of selective COX-2 inhibitors. In a placebo-controlled trial of pain relief after coronary-artery bypass surgery, the use of the parenteral COX-2 inhibitor parecoxib followed by oral treatment with its active metabolite valdecoxib, or treatment with placebo followed by valdecoxib, was associated with a significantly increased risk of cardiovascular thromboembolic events.31 In this issue of the Journal, Nussmeier et al. report a second trial showing a significant increase in cardiovascular events when parecoxib and valdecoxib were used in the immediate postoperative period after coronary-artery bypass surgery.32 The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) also showed a nonsignificant increase in the risk of cardiovascular events with lumiracoxib therapy,10 as compared with naproxen or ibuprofen therapy, but only among patients who were not taking aspirin.
In contrast, to our knowledge, neither pharmacoepidemiologic studies nor randomized, controlled trials have reported clear evidence of an increased cardiovascular risk associated with celecoxib. The failure of pharmacoepidemiologic studies to show an increased risk may be due in part to the lower doses and shorter duration of use in these studies than in clinical trials and in part to the potential for selection bias in nonrandomized studies. Nevertheless, the Celecoxib in Long-term Arthritis Safety Study (CLASS),2 which used the same dose of celecoxib (400 mg twice daily) that was given to one group in the APC study and compared celecoxib with two nonselective NSAIDs, did not show an increased rate of cardiovascular events.2 CLASS differed from the VIGOR study in several important ways. A short-term study not designed for systematic and formal assessment of cardiovascular events, CLASS enrolled relatively low-risk patients and allowed the use of aspirin for cardiovascular protection. In addition, FitzGerald has suggested that CLASS did not completely refute evidence of an increased cardiac risk associated with celecoxib use in non–aspirin users, as compared with those taking ibuprofen (but not diclofenac).20 Moreover, the results of a randomized, controlled clinical trial of celecoxib in patients with Alzheimer's disease, reported to the Food and Drug Administration, demonstrated an increase in cardiovascular events among patients receiving celecoxib.33
Although we found that patients with an increased cardiovascular risk at baseline appeared to have a higher absolute rate of events than those with no increase in cardiovascular risk at baseline, formal statistical tests of interaction showed no differential effect of celecoxib with respect to baseline cardiovascular risk. One prespecified subgroup included users of cardioprotective aspirin at baseline. Although the overall absolute risk appeared to be higher among such patients, analysis of the data on aspirin users in this study shows that they had a higher frequency of cardiovascular risk factors at baseline than did nonusers.
The cardiovascular findings with regard to celecoxib use in the APC study are consistent with those identified for rofecoxib use in the APPROVe trial. In contrast, preliminary analyses from the PreSAP trial, which involved a daily dose of 400 mg of celecoxib, showed no apparent increase in cardiovascular risk. The differences in the dosing regimens between these two trials — twice daily in the APC study, as compared with once daily in the PreSAP study — support the hypothesis that sustained inhibition of prostacyclin may contribute to the increase in cardiovascular risk. Other potential differences in the trials, including geographic differences, differences in the patient population, and differences in use of concomitant medications, may have contributed to the disparity in the preliminary findings.
The increased cardiovascular risk in the APC trial was based on a small number of events in a trial that was not designed or statistically powered to evaluate cardiovascular risk. Although we believe we have identified all adverse cardiovascular events, we cannot rule out the possibility that some events remained unreported. Our results must therefore be interpreted with caution.
Still, in the context of the results of the other trials reviewed involving agents in the same class, these data suggest that there may be a real increase in cardiovascular risk associated with the use of celecoxib in particular and the class of selective COX-2 inhibitors in general. If correct, this interpretation has substantial implications for public health,11,34 patient education,35 and drug regulation.36,37 Given the experience with COX-2 inhibitors, we support the call for regulatory agencies to consider requesting a formal evaluation of long-term cardiovascular outcomes of any new drug with a mechanism of action that could augment the risk of cardiac and vascular events, especially if many patients who are likely to use the new agent are prone to cardiovascular disease.25 This category may include nonselective NSAIDs (other than aspirin), as discussed earlier. More broadly, this experience underscores both the need for long-term, placebo-controlled trials to assess safety as well as efficacy and the need to improve methods for assessing potential adverse cardiovascular outcomes in studies with noncardiovascular primary end points.
In summary, a blinded review of cardiovascular events in a large, randomized, controlled study of two doses of celecoxib for the prevention of colorectal adenomas showed a dose-related risk of such events, including death from cardiovascular causes, myocardial infarction, stroke, and heart failure. In light of other recent reports of the adverse cardiovascular effects of other agents in this class, these data provide further evidence that long-term use of COX-2 inhibitors may increase the risk of serious cardiovascular events. These risks will need to be weighed against any potential benefits of celecoxib in preventing colorectal neoplasia and in relieving pain.
The APC was sponsored by the National Cancer Institute and cosponsored by Pfizer. This cardiovascular review was funded solely by the National Cancer Institute.
Drs. McMurray, Pfeffer, and Zauber report having received consulting fees from Pfizer. Drs. Solomon, McMurray, and Pfeffer report having received lecture fees from Pfizer. Dr. Wittes reports having received consulting fees from Merck within the past two years.
This article was published at www.nejm.org on February 15, 2005.
Source Information
From the Cardiovascular Division, Departments of Medicine (S.D.S., M.A.P., P.F.) and Surgery (M.B.), Brigham and Women's Hospital, Harvard Medical School, Boston; Western Infirmary, University of Glasgow, Glasgow, Scotland (J.J.V.M.); Statistics Collaborative, Washington, D.C. (J.W., R.F.); National Cancer Institute, Bethesda, Md. (W.F.A., E.H.); and Memorial Sloan-Kettering Cancer Center, New York (A.Z.).
Address reprint requests to Dr. Solomon at the Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at ssolomon@rics.bwh.harvard.edu.
Participants in the APC study are listed in the Appendix.
Appendix
The following persons participated in the APC Study: Steering Committee: M.M. Bertagnolli, E. Hawk, C. Eagle; Statistical Team: A. Zauber, K.M. Kim, D. Corle, R. Rosenstein, J. Tang, T. Hess, A. Wilton; Medical Monitors: W. Anderson, L. Doody; Central Pathology Review: M. Redston; Project Directors: M. Woloj, D. Bagheri, A. Crawford, M. Schietrum, V. Ladouceur; Data and Safety Monitoring Board: S. Rosen (chair), L. Friedman, R. Makuch, R. Phillips, P. Taylor; Principal Investigators: United States: S. Auerbach (California Professional Research, Newport Beach), C.F. Barish (Wake Research Associates, Raleigh, N.C.), T. Barringer (Carolinas Medical Center, Charlotte, N.C.), R.W. Bennetts (Northwest Gastroenterology Clinic, Portland, Oreg.), M. Blitstein (Associates in Gastroenterology and Liver Disease, Lake Forest, Ill.), J. Bruggen (Wake Forest University Baptist Medical Center, Winston-Salem, N.C.), P. Carricaburu (Veterans Affairs Hospital, Sheridan, Wyo.), D. Chung (Massachusetts General Hospital, Boston), F. Colizzo (Pentucket Medical Associates, Haverhill, Mass.), R. Curtis (Newton–Wellesley Hospital, Newton, Mass.), T. Dewar (Harris Methodist Hospital Fort Worth, Ft. Worth, Tex.), R. DuBois (Vanderbilt University Medical Center, Nashville), T. Feinstat (Gastroenterology Consultants of Sacramento, Roseville, Calif.), T.R. Foley (Regional Gastroenterology Associates of Lancaster, Lancaster, Pa.), D. Gabbaizadeh (Huntington Research Group, Huntington Station, N.Y.), J. Geenen (Wisconsin Center for Advanced Research, Milwaukee), F. Giardiello (Johns Hopkins Hospital, Baltimore), A. Goetsch (nTouch Research, Huntsville, Ala.), M. Goldberg (Regional Gastroenterology Associates of Lancaster, Evanston, Ill.), J.L. Goldstein (University of Illinois at Chicago, Chicago), W. Harlan, III (Asheville Gastroenterology Associates, Asheville, N.C.), R. Hogan (Gastrointestinal Associates, Jackson, Miss.), M. Kamionkowski (Gastroenterology Associates of Cleveland, Mayfield Heights, Ohio), M. Kelfer (Fallon Clinic, West Boylston, Mass.), B. Kerzner (Health Trends Research, Baltimore), K. Kim (University of Chicago Medical Center, Chicago), I. Klimberg (Gastroenterology Associates of Ocala, Ocala, Fla.), G. Koval (West Hills Gastroenterology Associates, Portland, Oreg.), C. Krone (Advanced Clinical Therapeutics, Tucson, Ariz.), S. Krumholz (Waterside Clinical Research, West Palm Beach, Fla.), M.W. Layton (South Puget Sound Clinical Research Center, Olympia, Wash.), C. Lightdale (Columbia-Presbyterian Medical Center, New York), P.J. Limburg (Mayo Clinic, Rochester, Minn.), C. Lind (Vanderbilt University Medical Center, Nashville), D. Lipkis (Institute for Health Care Assessment, San Diego, Calif.), M. Lloyd (Idaho Gastroenterology, Meridian), D. Maccini (Spokane Digestive Disease Center, Spokane, Wash.), F. MacMilan, Sr. (Pentucket Medical Associates, Haverhill, Mass.), R. Madoff (University of Minnesota, Minneapolis), A. Malik (Advanced Clinical Research, North Providence, R.I.), A. Markowitz (Memorial Sloan-Kettering Cancer Center, New York), R. Marks (Alabama Digestive Research Center, Alabaster), C.J. McDougall (Manhattan Associates, New York), P. Miner (Oklahoma Foundation for Digestive Research, Oklahoma City), M. Murphy (Southeastern Digestive and Liver Disease Institute, Savannah, Ga.), A. Namias (Gastrointestinal Physicians, Salem, Mass.), N. Nickl (University of Kentucky Medical Center, Lexington), M. Pochapin (Jay Monahan Center for Gastrointestinal Health, New York), R.E. Pruitt (Nashville Medical Research Institute, Nashville), J. Puolos (Cumberland Research Associates, Fayetteville, N.C.), D.S. Riff (AGMG Clinical Research, Anaheim, Calif.), R. Roman (South Denver Gastroenterology, Englewood, Colo.), L. Rubin (New Jersey Physicians, Passaic), D. Ruff (Healthcare Discoveries, San Antonio, Tex.), M. Safdi (Consultants for Clinical Research, Cincinnati), J. Saltzman (Brigham and Women's Hospital, Boston), B. Salzberg (Atlanta Gastroenterology Associates, Atlanta), J.A. Sattler (Western Clinical Research, Torrance, Calif.), P. Schleinitz (Americas Doctors Research, Medford, Oreg.), J. Schwartz (Northwest Gastroenterologists, Arlington Heights, Ill.), M. Schwartz (Jupiter Research Association, Jupiter, Fla.), M. Silpa (Gastroenterology Associates of The East Bay Medical Group, Berkeley, Calif.), D. Silvers (Drug Research Services, Metairie, La.), D. Smoot (Howard University Cancer Center, Washington, D.C.), S. Sontag (Veterans Affairs Medical Center, Hines, Ill.), R.J. Sorrell (Gastroenterology Specialties, Lincoln, Nebr.), D. Stanton (Community Clinical Trials, Orange, Calif.), J. Sturgeon (Americas Doctors Research, Shawnee Mission, Kans.), J.P. Tracey (Hawthorne Medical Associates, North Dartmouth, Mass.), T. Werth (Charlotte Gastroenterology and Hepatology, Charlotte, N.C.), C.M. Wilcox (University of Alabama at Birmingham, Birmingham), R. Wohlman (Northwest Gastroenterology Associates, Bellevue, Wash.), S. Woods (Gastroenterology Associates of Fairfield County, Bridgeport, Conn.); United Kingdom: J. Burn (South Cleveland Hospital, Middlesbrough); Australia: H. Ee (Sir Charles Gairdner Hospital, Nedlands, W.A.), M. Korman (Monash Medical Centre, Clayton, Victoria), A. Lee (Concord Repatriation and General Hospital, Concord, N.S.W.), B. Leggett (Royal Brisbane Hospital, Herston, Queensland), F. Macrae (Royal Melbourne Hospital, Melbourne, Victoria), L. Mollison (Freemantle Hospital, Freemantle, W.A.), N. Yeomans (Western Hospital, Footscray, Victoria), G. Young (Flinders Medical Centre, Bedford, S.A.); Canada: G. Aumais (Hospital Maisonneuve-Rosemont, Montreal), R. Bailey (Hys Medical Centre, Edmonton, Alta.), C. Bernstein (Winnipeg Health Sciences Centre, Winnipeg, Man.), L. Cohen (Sunnybrook and Women's Hospital, Toronto), C. Dallaire, R. Dube (Centre Hospitalier Universitaire de Quebec, Quebec, Que.), D. Morgan (McMaster University, Hamilton, Ont.), T. Sylwestrowicz (St. Paul's Hospital, Saskatoon, Sask.), G. Van Rosendaal (University of Calgary Health Sciences Centre, Calgary, Alta.), S.J. Van Zantan (Queen Elizabeth II Health Sciences Centre, Halifax, N.S.).
- References
References
1
Marnett LJ ,Rowlinson SW ,Goodwin DC ,Kalgutkar AS ,Lanzo CA . Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem 1999;274:22903-22906
CrossRef | Web of Science | Medline2
Silverstein FE ,Faich G ,Goldstein JL , et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-1255
CrossRef | Web of Science | Medline3
Bombardier C ,Laine L ,Reicin A , et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528
Full Text | Web of Science | Medline4
Marnett LJ ,Kalgutkar AS . Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci 1999;20:465-469
CrossRef | Web of Science | Medline5
Steinbach G ,Lynch PM ,Phillips RKS , et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952
Full Text | Web of Science | Medline6
Giardiello FM ,Yang VW ,Hylind LM , et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059
Full Text | Web of Science | Medline7
Baron JA . Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003;37:1-24
CrossRef | Web of Science | Medline8
Hawk ET ,Viner J ,Richmond E ,Umar A . Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif 2003;21:759-789
Medline9
FitzGerald GA ,Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442
Full Text | Web of Science | Medline10
FitzGerald GA . Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711
Full Text | Web of Science | Medline11
Topol EJ ,Falk GW . A coxib a day won't keep the doctor away. Lancet 2004;364:639-640
CrossRef | Web of Science | Medline12
White WB ,Faich G ,Borer JS ,Makuch RW . Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411-418
CrossRef | Web of Science | Medline13
Mamdani M ,Juurlink DN ,Lee DS , et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751-1756
CrossRef | Web of Science | Medline14
Solomon DH ,Schneeweiss S ,Glynn RJ , et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-2073
CrossRef | Web of Science | Medline15
Ray WA ,Stein CM ,Daugherty JR ,Hall K ,Arbogast PG ,Griffin MR . COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-1073
CrossRef | Web of Science | Medline16
Mamdani M ,Rochon P ,Juurlink DN , et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-486
CrossRef | Web of Science | Medline17
Furberg CD ,Psaty BM ,FitzGerald GA . Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005;111:249-249
CrossRef | Web of Science | Medline18
Juni P ,Nartey L ,Reichenbach S ,Sterchi R ,Dieppe PA ,Egger M . Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-2029
CrossRef | Web of Science | Medline19
Crofford LJ ,Lipsky PE ,Brooks P ,Abramson SB ,Simon LS ,van de Putte LB . Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13
CrossRef | Web of Science | Medline20
FitzGerald GA . COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890
CrossRef | Web of Science | Medline21
McAdam BF ,Catella-Lawson F ,Mardini IA ,Kapoor S ,Lawson JA ,FitzGerald GA . Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277[Erratum, Proc Natl Acad Sci U S A 1999;96:5890.]
CrossRef | Web of Science | Medline22
Brock TG ,McNish RW ,Peters-Golden M . Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999;274:11660-11666
CrossRef | Web of Science | Medline23
Chenevard R ,Hurlimann D ,Bechir M , et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-409
CrossRef | Web of Science | Medline24
Farkouh ME ,Kirshner H ,Harrington RA , et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-684
CrossRef | Web of Science | Medline25
Zhao SZ ,Burke TA ,Whelton A ,von Allmen H ,Henderson SC . Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Am J Manag Care 2002;8:Suppl:S392-S400
Web of Science | Medline26
Bresalier RS ,Sandler RS ,Quan H , et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102
Full Text | Web of Science | Medline27
Mukherjee D ,Nissen SE ,Topol EJ . Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959
CrossRef | Web of Science | Medline28
Weir MR ,Sperling RS ,Reicin A ,Gertz BJ . Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003;146:591-604
CrossRef | Web of Science | Medline29
Konstam MA ,Weir MR ,Reicin A , et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-2288
CrossRef | Web of Science | Medline30
Topol EJ . Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:2877-2878
Full Text | Web of Science31
Ott E ,Nussmeier NA ,Duke PC , et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-1492
CrossRef | Web of Science | Medline32
Nussmeier NA ,Whelton AA ,Brown MT , et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091
Full Text | Web of Science | Medline33
Celecoxib. PhRMA IQ5-97-02-001. (Accessed February 18, 2005, at http://www.clinicalstudyresults.org/documents/company-study_76_0.pdf.)
34
Topol EJ . Failing the public health -- rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709
Full Text | Web of Science | Medline35
Dieppe PA ,Ebrahim S ,Martin RM ,Juni P . Lessons from the withdrawal of rofecoxib. BMJ 2004;329:867-868
CrossRef | Web of Science | Medline36
Josefson D . FDA warns Merck over its promotion of rofecoxib. BMJ 2001;323:767-767
CrossRef | Web of Science | Medline37
Mukherjee D ,Topol EJ . Pharmaceutical advertising versus research spending: are profits more important than patients? Am Heart J 2003;146:563-564
CrossRef | Web of Science | Medline
- Citing Articles (629)
Citing Articles
1
Jenny T. Mao, Ravi Durvasula. (2012) Lung cancer chemoprevention: current status and future directions. Current Respiratory Care Reports
CrossRef2
M. J. D. Prins, R. J. J. Verhage, F. J. W. Kate, R. Hillegersberg. (2012) Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma. Journal of Gastrointestinal Surgery
CrossRef3
Waseem Khaliq, Kala Visvanathan. (2012) Breast Cancer Chemoprevention: Current Approachesand Future Directions. Current Obstetrics and Gynecology Reports
CrossRef4
Guanglin Cui, Yingpeng Shi, Jing Cui, Fuai Tang, Jon Florholmen. (2012) Immune microenvironmental shift along human colorectal adenoma–carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets?. Scandinavian Journal of Gastroenterology1-11
CrossRef5
Mary-Clare Cathcart, Kenneth J. O'Byrne, John V. Reynolds, Jacintha O'Sullivan, Graham P. Pidgeon. (2012) COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1825:1, 49-63
CrossRef6
Andrew S. Chi, Patrick Y. Wen. 2012. Inhibiting angiogenesis in malignant gliomas. , 279-308.
CrossRef7
Anita Holdcroft. 2011. Pain Management Market Overview. .
CrossRef8
Kiyoshi Hasegawa, Yutaka Torii, Risa Ishii, Shuko Oe, Rina Kato, Yasuhiro Udagawa. (2011) Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Archives of Gynecology and Obstetrics 284:6, 1515-1521
CrossRef9
Aristóteles Rosmaninho, Inês Lobo, Manuela Selores. (2011) Sweet’s syndrome associated with the intake of a selective cyclooxygenase-2 (COX-2) inhibitor. Cutaneous and Ocular Toxicology 30:4, 298-301
CrossRef10
Thor Hallingbye, Jacob Martin, Christopher Viscomi. (2011) Acute postoperative pain management in the older patient. Aging Health 7:6, 813-828
CrossRef11
Paul L. McCormack. (2011) Celecoxib. Drugs 71:18, 2457-2489
CrossRef12
Mary-Clare Cathcart, Joanne Lysaght, Graham P. Pidgeon. (2011) Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer and Metastasis Reviews 30:3-4, 363-385
CrossRef13
B.C. Garrido López, F. Navarro Sarabia, E.M. Montero Martín. (2011) Antiinflamatorios no esteroideos: farmacodinámica, reacciones adversas e indicaciones en reumatología. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6255-6261
CrossRef14
Nulgumnalli Manjunathaiah Raghavendra, Aitha Jyothsna, Alapati Venkateswara Rao, C.V.S. Subrahmanyam. (2011) Synthesis, pharmacological evaluation and docking studies of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs as COX-2 inhibitors. Bioorganic & Medicinal Chemistry Letters
CrossRef15
M. Back, L. Yin, E. Ingelsson. (2011) Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European Heart Journal
CrossRef16
Luigi Piero Stasi, Kanji Bhimani, Manuela Borriello, Luca Canciani, Gianfranco Caselli, Fabrizio Colace, Cristian Ferioli, Mehul Kaswala, Laura Mennuni, Tiziana Piepoli, Sabrina Pucci, Matteo Salvi, Vikas Shirsath, Tiziano Zanelli, Silvia Zerbi. (2011) Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor. Bioorganic & Medicinal Chemistry Letters 21:21, 6336-6340
CrossRef17
Paul E. Stang, Patrick B. Ryan, Stacie B. Dusetzina, Abraham G. Hartzema, Christian Reich, J. Marc Overhage, Judith A. Racoosin. (2011) Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine
CrossRef18
Karin Müller-Decker. (2011) Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer and Metastasis Reviews
CrossRef19
Alexandra Thiel, Johanna Mrena, Ari Ristimäki. (2011) Cyclooxygenase-2 and Gastric Cancer. Cancer and Metastasis Reviews
CrossRef20
Elmar Friderichs, Thomas Christoph, Helmut Buschmann. 2011. Analgesics and Antipyretics, 2. Nonsteroidal Anti-inflammatory Drugs. .
CrossRef21
Jocelyn Reader, Dawn Holt, Amy Fulton. (2011) Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer and Metastasis Reviews
CrossRef22
Claudia Bocca, Francesca Bozzo, Monica Ievolella, Antonella Miglietta. (2011) A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth. Molecular and Cellular Biochemistry
CrossRef23
Sukanya Mitra, Purva Khandelwal, Kurt Roberts, Salil Kumar, Nalini Vadivelu. (2011) Pain Relief in Laparoscopic Cholecystectomy-A Review of the Current Options. Pain Practiceno-no
CrossRef24
N. Markosyan, E. P. Chen, V. N. Ndong, Y. Yao, C. J. Sterner, L. A. Chodosh, J. A. Lawson, G. A. FitzGerald, E. M. Smyth. (2011) Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 32:10, 1441-1449
CrossRef25
Nam-Kyong Choi, Yoosoo Chang, Ju-Young Kim, Yu-Kyong Choi, Byung-Joo Park. (2011) Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef26
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Antoine Pariente, Lorenza Scotti, Miriam Sturkenboom, Susana Perez-Gutthann. (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef27
Hui-Hua Chang, Zuohe Song, Lee Wisner, Tina Tripp, Vijay Gokhale, Emmanuelle J. Meuillet. (2011) Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers. Investigational New Drugs
CrossRef28
Gudrun Stefansdottir, Marie L. De Bruin, Mirjam J. Knol, Diederick E. Grobbee, Hubert G.M. Leufkens. (2011) Randomized Controlled Trials of COX-2 Inhibitors. Drug Safety 34:9, 783-792
CrossRef29
William B. White, Christina Cruz. (2011) Impact of NSAIDs on cardiovascular risk and hypertension. Italian Journal of Medicine 5:3, 175-183
CrossRef30
Paola Patrignani, Stefania Tacconelli, Annalisa Bruno, Carlos Sostres, Angel Lanas. (2011) Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Review of Clinical Pharmacology 4:5, 605-621
CrossRef31
Maryam B. Lustberg, Stephen P. Povoski, Weiqiang Zhao, Rebecca M. Ziegler, Yasuro Sugimoto, Amy S. Ruppert, Amy M. Lehman, Donna R. Shiels, Ewa Mrozek, Bhuvaneswari Ramaswamy, Rachel M. Layman, Robert W. Brueggemeier, Charles L. Shapiro. (2011) Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 11:4, 221-227
CrossRef32
Seong Jun Park, Helmut Buschmann, Carsten Bolm. (2011) Bioactive sulfoximines: Syntheses and properties of Vioxx® analogs. Bioorganic & Medicinal Chemistry Letters 21:16, 4888-4890
CrossRef33
I. Bozovic-Spasojevic, E. Azambuja, Worta McCaskill-Stevens, P. Dinh, F. Cardoso. (2011) Chemoprevention for breast cancer. Cancer Treatment Reviews
CrossRef34
Emily R. Greene, Sui Huang, Charles N. Serhan, Dipak Panigrahy. (2011) Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators
CrossRef35
Xiangwei Wu, Sherri Patterson, Ernest Hawk. (2011) Chemoprevention – History and general principles. Best Practice & Research Clinical Gastroenterology 25:4-5, 445-459
CrossRef36
Brian Kim, Francis M. Giardiello. (2011) Chemoprevention in familial adenomatous polyposis. Best Practice & Research Clinical Gastroenterology 25:4-5, 607-622
CrossRef37
Menachem Moshkowitz, Shiran Shapira, Nadir Arber. (2011) Chemoprevention for advanced CR neoplasia. Best Practice & Research Clinical Gastroenterology 25:4-5, 623-630
CrossRef38
Z Adhim, T Matsuoka, T Bito, K Shigemura, K-M Lee, M Kawabata, M Fujisawa, K Nibu, T Shirakawa. (2011) In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. British Journal of Cancer 105:3, 393-402
CrossRef39
Y Vinogradova, C Coupland, J Hippisley-Cox. (2011) Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case–control studies. British Journal of Cancer 105:3, 452-459
CrossRef40
Aude-Hélène Capietto, Ludovic Martinet, Jean-Jacques Fournié. (2011) How tumors might withstand γδ T-cell attack. Cellular and Molecular Life Sciences 68:14, 2433-2442
CrossRef41
Ying Wang, Feng Yang, Yang-Feng Liu, Fei Gao, Wen Jiang. (2011) Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neuroscience Letters 499:2, 74-79
CrossRef42
B Liu, J K Wen, B H Li, X M Fang, J J Wang, Y P Zhang, C J Shi, D Q Zhang, M Han. (2011) Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death and Disease 2:7, e185
CrossRef43
Sawsan A Zaitone, Yasser M Moustafa, Sarah M Mosaad, Naglaa F El-Orabi. (2011) Effect of Evening Primrose Oil and Omega-3 Polyunsaturated Fatty Acids on the Cardiovascular Risk of Celecoxib in Rats. Journal of Cardiovascular Pharmacology 58:1, 72-79
CrossRef44
Anthony A. Bavry, Asma Khaliq, Yan Gong, Eileen M. Handberg, Rhonda M. Cooper-DeHoff, Carl J. Pepine. (2011) Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease. The American Journal of Medicine 124:7, 614-620
CrossRef45
Goss, Paul E., Ingle, James N., Alés-Martínez, José E., Cheung, Angela M., Chlebowski, Rowan T., Wactawski-Wende, Jean, McTiernan, Anne, Robbins, John, Johnson, Karen C., Martin, Lisa W., Winquist, Eric, Sarto, Gloria E., Garber, Judy E., Fabian, Carol J., Pujol, Pascal, Maunsell, Elizabeth, Farmer, Patricia, Gelmon, Karen A., Tu, Dongsheng, Richardson, Harriet, . (2011) Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine 364:25, 2381-2391
Full Text46
B.K. Sharma, P. Singh, P. Pilania, M. Shekhawat, Y.S. Prabhakar. (2011) QSAR of 2-(4-methylsulphonylphenyl)pyrimidine derivatives as cyclooxygenase-2 inhibitors: simple structural fragments as potential modulators of activity. Journal of Enzyme Inhibition and Medicinal Chemistry1-12
CrossRef47
O A Khan, A D Blann, M J Payne, M R Middleton, A S Protheroe, D C Talbot, M Taylor, C Han, M Patil, A L Harris. (2011) Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. British Journal of Cancer 104:12, 1822-1827
CrossRef48
Nasser K. Altorki, Paul Christos, Jeff L. Port, Paul C. Lee, Farooq Mirza, Cathy Spinelli, Roger Keresztes, Debra Beneck, Subroto Paul, Brendon M. Stiles, Yuwei Zhang, David S. Schrump. (2011) Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology 6:6, 1121-1127
CrossRef49
Stephen J. Kerr, Debra S. Rowett, Geoffrey P. Sayer, Susan D. Whicker, Deborah C. Saltman, Andrea Mant. (2011) All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study. British Journal of Clinical Pharmacology 71:6, 936-942
CrossRef50
Sara Biere-Rafi, Marcello Di Nisio, Victor Gerdes, Ettore Porreca, Patrick Souverein, Anthonius Boer, Harry Büller, Pieter Kamphuisen. (2011) Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiology and Drug Safety 20:6, 635-642
CrossRef51
Tsui-Ting Ching, Wei-Chung Chiang, Ching-Shih Chen, Ao-Lin Hsu. (2011) Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. Aging Cell 10:3, 506-519
CrossRef52
E. Blommers, M. Klimek, K.A. Hartholt, T.J.M. Cammen, J. Klein, P.G. Noordzij. (2011) Perioperative care of the older patient. Zeitschrift für Gerontologie und Geriatrie 44:3, 187-191
CrossRef53
Olivier Barthélémy, Tobias Limbourg, Jean Philippe Collet, Farzin Beygui, Johanne Silvain, Anne Bellemain-Appaix, Guillaume Cayla, Thomas Chastre, Iris Baumgartner, Joachim Röther, Uwe Zeymer, Deepak L. Bhatt, Gabriel Steg, Gilles Montalescot. (2011) Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. International Journal of Cardiology
CrossRef54
Henry Krum, Gary Swergold, Arnold Gammaitoni, Paul M. Peloso, Steven S. Smugar, Sean P. Curtis, D. Craig Brater, Hongwei Wang, Amarjot Kaur, Loren Laine, Matthew R. Weir, Christopher P. Cannon. (2011) Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. Cardiovascular Therapeuticsno-no
CrossRef55
Vivian Y. Shin, Hong C. Jin, Enders K. O. Ng, Chi H. Cho, Wai K. Leung, Joseph J. Y. Sung, Kent-Man Chu. (2011) 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro. Cancer Science 102:5, 926-933
CrossRef56
Mi-Kyung Kim, Kidong Kim, Jae Yong Han, Jeong Mook Lim, Yong Sang Song. (2011) Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes & Nutrition 6:2, 109-115
CrossRef57
Morten Schmidt, Lars Pedersen, Michael Maeng, Jens F Lassen, Timothy L Lash, Torsten T Nielsen, Henrik T Sørensen. (2011) Nonsteroidal Antiinflammatory Drug Use and Cardiovascular Risks After Coronary Stent Implantation. Pharmacotherapy 31:5, 458-468
CrossRef58
Yuhua Li, Li Liu, Yinbo Niu, Juan Feng, Yang Sun, Xianghe Kong, Yongchun Chen, Xiaoyan Chen, Hongquan Gan, Shousong Cao, Qibing Mei. (2011) Modified apple polysaccharide prevents against tumorigenesis in a mouse model of colitis-associated colon cancer: role of galectin-3 and apoptosis in cancer prevention. European Journal of Nutrition
CrossRef59
Ho June Song, Seung-Jae Myung, In-Wha Kim, Jin-Yong Jeong, Young Soo Park, Sun Mi Lee, Won Hee Nam, Yeon-Mi Ryu, Stephen P. Fink, Dong-Hoon Yang, Hwoon-Yong Jung, Jin-Ho Kim. (2011) 15-Hydroxyprostaglandin Dehydrogenase is Downregulated and Exhibits Tumor Suppressor Activity in Gastric Cancer. Cancer Investigation 29:4, 257-265
CrossRef60
Kevin K. Tremper. (2011) Anesthesiology: From Patient Safety to Population Outcomes. Anesthesiology 114:4, 755-770
CrossRef61
S.U. Monrad, F. Kojima, M. Kapoor, E.L. Kuan, S. Sarkar, G.J. Randolph, L.J. Crofford. (2011) Genetic deletion of mPGES-1 abolishes PGE2 production in murine dendritic cells and alters the cytokine profile, but does not affect maturation or migration. Prostaglandins, Leukotrienes and Essential Fatty Acids 84:3-4, 113-121
CrossRef62
Dao-jie Xu, Ji-wen Bu, Shan-ye Gu, Yi-meng Xia, Jiu-lin Du, Ying-wei Wang. (2011) Celecoxib Impairs Heart Development via Inhibiting Cyclooxygenase-2 Activity in Zebrafish Embryos. Anesthesiology 114:2, 391-400
CrossRef63
Jason D. Burch, Julie Farand, John Colucci, Claudio Sturino, Yves Ducharme, Richard W. Friesen, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Alex G. Therien, Marie-Claude Mathieu, Danielle Denis, Erika Vigneault, Daigen Xu, Patsy Clark, Steve Rowland, Yongxin Han. (2011) Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor. Bioorganic & Medicinal Chemistry Letters 21:3, 1041-1046
CrossRef64
Hong Cai, Stewart Sale, Robert G. Britton, Karen Brown, William P. Steward, Andreas J. Gescher. (2011) Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone). Cancer Chemotherapy and Pharmacology 67:2, 255-263
CrossRef65
Norman T. Ilowite, Ronald M. Laxer. 2011. PHARMACOLOGY AND DRUG THERAPY. , 71-126.
CrossRef66
Mary-Clare Cathcart, Kathy Gately, Robert Cummins, Elaine Kay, Kenneth J O'Byrne, Graham P Pidgeon. (2011) Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer 10:1, 25
CrossRef67
Chi-Tai Yeh, Chih-Jung Yao, Jiann-Long Yan, Shuang-En Chuang, Liang-Ming Lee, Chien-Ming Chen, Chuan-Feng Yeh, Chi-Han Li, Gi-Ming Lai. (2011) Apoptotic Cell Death and Inhibition of Wnt/β-Catenin Signaling Pathway in Human Colon Cancer Cells by an Active Fraction (HS7) from Taiwanofungus camphoratus. Evidence-Based Complementary and Alternative Medicine 2011, 1-13
CrossRef68
H. Pieringer, M. Pichler. (2011) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104:1, 13-26
CrossRef69
Francesco Legge, Amelia Paglia, Marco D'Asta, Gilda Fuoco, Giovanni Scambia, Gabriella Ferrandina. (2011) Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 11:1, 214
CrossRef70
Alexandra Thiel, Kirsi Narko, Mira Heinonen, Annabrita Hemmes, Catherine Tomasetto, Marie-Christine Rio, Caj Haglund, Tomi P. Mäkelä, Ari Ristimäki. (2011) Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. International Journal of Cancern/a-n/a
CrossRef71
Ryo Kawata. (2011) Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 by head and neck squamous cell carcinoma. Journal of Japan Society of Immunology & Allergology in Otolaryngology 29:4, 233-239
CrossRef72
Kirsten Lauber, Luis E. Munoz, Christian Berens, Verena Jendrossek, Claus Belka, Martin Herrmann. (2011) Apoptosis induction and tumor cell repopulation: The yin and yang of radiotherapy. Radiation Oncology 6:1, 176
CrossRef73
C. A. Elmets, J. L. Viner, A. P. Pentland, W. Cantrell, H.-Y. Lin, H. Bailey, S. Kang, K. G. Linden, M. Heffernan, M. Duvic, E. Richmond, B. E. Elewski, A. Umar, W. Bell, G. B. Gordon. (2010) Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI Journal of the National Cancer Institute 102:24, 1835-1844
CrossRef74
Vidushi S. Neergheen, Theeshan Bahorun, Ethan Will Taylor, Ling-Sun Jen, Okezie I. Aruoma. (2010) Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 278:2, 229-241
CrossRef75
Conan MacDougall, Tamar Udkow, B. Joseph Guglielmo, Eric Vittinghoff, Jeffrey Martin. (2010) National estimates and predictors of prescription medication sample use in the United States, 1999-2005. Journal of the American Pharmacists Association 50:6, 677-685
CrossRef76
Michael P. Robich, Louis M. Chu, Jun Feng, Thomas A. Burgess, Roger J. Laham, Cesario Bianchi, Frank W. Sellke. (2010) Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. The Journal of Thoracic and Cardiovascular Surgery 140:5, 1143-1152
CrossRef77
Louis Ragolia, Thomas Palaia, Christopher E. Hall, Jonathan Klein, Arzu Büyük. (2010) Diminished lipocalin-type prostaglandin D2 synthase expression in human lung tumors. Lung Cancer 70:1, 103-109
CrossRef78
Harvey G. Moore. (2010) Colorectal Cancer: What Should Patients and Families Be Told to Lower the Risk of Colorectal Cancer?. Surgical Oncology Clinics of North America 19:4, 693-710
CrossRef79
A Strillacci, C Griffoni, G Lazzarini, M C Valerii, S Di Molfetta, F Rizzello, M Campieri, M P Moyer, V Tomasi, E Spisni. (2010) Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells. British Journal of Cancer 103:7, 975-986
CrossRef80
Vincent E. Friedewald, Joel S. Bennett, J. Paul Christo, James L. Pool, James M. Scheiman, Lee S. Simon, Vibeke Strand, William B. White, Gary W. Williams, William C. Roberts. (2010) AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology 106:6, 873-884
CrossRef81
Frank De Vries, Efrosini Setakis, Tjeerd-Pieter Van Staa. (2010) Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. British Journal of Clinical Pharmacology 70:3, 429-438
CrossRef82
Rabindra N. Bhattacharjee, Alexander V. Timoshenko, Jing Cai, Peeyush K. Lala. (2010) Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Science 101:9, 2026-2032
CrossRef83
Alberto Pilotto, Daniele Sancarlo, Filomena Addante, Carlo Scarcelli, Marilisa Franceschi. (2010) Non-steroidal anti-inflammatory drug use in the elderly. Surgical Oncology 19:3, 167-172
CrossRef84
Kyriakos N. Papanicolaou, John M. Streicher, Tomo-o Ishikawa, Harvey Herschman, Yibin Wang, Kenneth Walsh. (2010) Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. Journal of Molecular and Cellular Cardiology 49:2, 196-209
CrossRef85
Ji-Hye Yoo, Hee Ju Lee, Kyungsu Kang, Eun Hye Jho, Chul Young Kim, Dulamjav Baturen, Jigjidsuren Tunsag, Chu Won Nho. (2010) Lignans inhibit cell growth via regulation of Wnt/β-catenin signaling. Food and Chemical Toxicology 48:8-9, 2247-2252
CrossRef86
Miao Wang, Garret A. FitzGerald. (2010) Cardiovascular Biology of Microsomal Prostaglandin E Synthase-1. Trends in Cardiovascular Medicine 20:6, 189-195
CrossRef87
Megan M Garrity-Park, Edward V Loftus, William J Sandborn, Sandra C Bryant, Thomas C Smyrk. (2010) Methylation Status of Genes in Non-Neoplastic Mucosa From Patients With Ulcerative Colitis-Associated Colorectal Cancer. The American Journal of Gastroenterology 105:7, 1610-1619
CrossRef88
Muhammad Amer, Valeriani R. Bead, Joan Bathon, Roger S. Blumenthal, David N. Edwards. (2010) Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease. Cardiology in Review 18:4, 204-212
CrossRef89
Peter Jones, Rain Lamdin. (2010) Oral Cyclo-Oxygenase 2 Inhibitors versus Other Oral Analgesics for Acute Soft Tissue Injury. Clinical Drug Investigation 30:7, 419-437
CrossRef90
Cynthia L. Feucht, Dilip R. Patel. (2010) Analgesics and Anti-inflammatory Medications in Sports: Use and Abuse. Pediatric Clinics of North America 57:3, 751-774
CrossRef91
John Colucci, Michael Boyd, Carl Berthelette, Jean-Francois Chiasson, Zhaoyin Wang, Yves Ducharme, Rick Friesen, Mark Wrona, Jean-Francois Levesque, Danielle Denis, Marie-Claude Mathieu, Rino Stocco, Alex G. Therien, Patsy Clarke, Steve Rowland, Daigen Xu, Yongxin Han. (2010) Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorganic & Medicinal Chemistry Letters 20:12, 3760-3763
CrossRef92
V. E. VALKHOFF, E. M. VAN SOEST, M. C. J. M. STURKENBOOM, E. J. KUIPERS. (2010) Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Alimentary Pharmacology & Therapeutics 31:11, 1218-1228
CrossRef93
Patrick M Lynch, Gregory D Ayers, Ernie Hawk, Ellen Richmond, Craig Eagle, Mabel Woloj, James Church, Hennie Hasson, Sherri Patterson, Elizabeth Half, Carol A Burke. (2010) The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis. The American Journal of Gastroenterology 105:6, 1437-1443
CrossRef94
Bjorn Gudbjornsson, Sigurdur B. Thorsteinsson, Helgi Sigvaldason, Rannveig Einarsdottir, Magnus Johannsson, Helga Zoega, Matthias Halldorsson, Gudmundur Thorgeirsson. (2010) Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults—a nationwide registry-based study. European Journal of Clinical Pharmacology 66:6, 619-625
CrossRef95
Masako Nakanishi, Vijay Gokhale, Emmanuelle J. Meuillet, Daniel W. Rosenberg. (2010) mPGES-1 as a target for cancer suppression. Biochimie 92:6, 660-664
CrossRef96
R. Ward. (2010) Identifying and assessing benefit-risk in primary care--a family physician's perspective. Rheumatology 49:Supplement 2, ii18-ii23
CrossRef97
J. W. J. Bijlsma. (2010) Patient benefit-risk in arthritis--a rheumatologist's perspective. Rheumatology 49:Supplement 2, ii11-ii17
CrossRef98
Anna L. Blobaum, Lawrence J. Marnett. 2010. NSAID Action and the Foundations for Cardiovascular Toxicity. , 257-285.
CrossRef99
Asli Deniz, Asli Sade, Feride Severcan, Dilek Keskin, Aysen Tezcaner, Sreeparna Banerjee. (2010) Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Bioscience Reports 30:5, 365-373
CrossRef100
Antonio González-Pérez, Luis Alberto García Rodriguez. 2010. Cardiovascular Toxicities of NSAIDS: Epidemiologic Aspects. , 287-312.
CrossRef101
Keshetty Srisailam, Ciddi Veeresham. (2010) Biotransformation of Celecoxib Using Microbial Cultures. Applied Biochemistry and Biotechnology 160:7, 2075-2089
CrossRef102
Carlos Sostres, Carla J. Gargallo, Maria T. Arroyo, Angel Lanas. (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Practice & Research Clinical Gastroenterology 24:2, 121-132
CrossRef103
Emer M Smyth. (2010) Thromboxane and the thromboxane receptor in cardiovascular disease. Clinical Lipidology 5:2, 209-219
CrossRef104
Christian Torp-Pedersen, Ole Dyg Pedersen, Lars Køber. (2010) Antiarrhythmic Drugs. Journal of the American College of Cardiology 55:15, 1577-1579
CrossRef105
Andrew Liuni, Mary Clare Luca, Tommaso Gori, John D. Parker. (2010) Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2–Dependent Mechanism. Journal of the American College of Cardiology 55:10, 1002-1006
CrossRef106
EMILY Y. CHEW, JONGHYEON KIM, HANNA R. COLEMAN, LLOYD PAUL AIELLO, GARY FISH, MICHAEL IP, JULIA A. HALLER, MARIA FIGUEROA, DANIEL MARTIN, DAVID CALLANAN, ROBERT AVERY, KERI HAMMEL, DARBY J. S. THOMPSON, FREDERICK L. FERRIS. (2010) PRELIMINARY ASSESSMENT OF CELECOXIB AND MICRODIODE PULSE LASER TREATMENT OF DIABETIC MACULAR EDEMA. Retina 30:3, 459-467
CrossRef107
Luciana B. Gentile, Bruno Piva, Bianca C. Capizzani, Luiz G.B. Furlaneto, Luciana S. Moreira, Daniel Zamith-Miranda, Bruno L. Diaz. (2010) Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: Role of cytosolic phospholipase A2-α and kinase signaling pathways. Prostaglandins, Leukotrienes and Essential Fatty Acids 82:2-3, 131-139
CrossRef108
Ernest Hawk, Sherri Patterson. (2010) Aspirin: anticolorectal adenocarcinoma activity in the adjuvant arena?. Future Oncology 6:2, 197-200
CrossRef109
Linda A. Feagins, Byron L. Cryer. (2010) Do Non-steroidal Anti-inflammatory Drugs Cause Exacerbations of Inflammatory Bowel Disease?. Digestive Diseases and Sciences 55:2, 226-232
CrossRef110
Harald E. Vonkeman, Mart A.F.J. van de Laar. (2010) Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Seminars in Arthritis and Rheumatism 39:4, 294-312
CrossRef111
Y.M. Schrage, I. Machado, D. Meijer, I. Briaire-de Bruijn, B.E. van den Akker, A.H.M. Taminiau, T. Kalinski, A. Llombart-Bosch, J.V.M.G. Bovée. (2010) COX-2 expression in chondrosarcoma: A role for celecoxib treatment?. European Journal of Cancer 46:3, 616-624
CrossRef112
A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora, D. M. Noonan. (2010) Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention. JNCI Journal of the National Cancer Institute 102:1, 14-25
CrossRef113
Sarah Kraus, Nadir Arber. (2010) Insights From the Adenoma Prevention With Celecoxib Trial and Risk for Cardiovascular Adverse Events. Current Colorectal Cancer Reports 6:1, 1-3
CrossRef114
Antonio Strillacci, Cristiana Griffoni, Maria Chiara Valerii, Giorgia Lazzarini, Vittorio Tomasi, Enzo Spisni. (2010) RNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer. Journal of Biomedicine and Biotechnology 2010, 1-12
CrossRef115
Reinhold W. Stockbrugger. (2010) Targeting Chemoprevention of Colorectal Cancer to Those Who Are Likely to Respond. Current Colorectal Cancer Reports 6:1, 44-47
CrossRef116
Hiroko Kariyazono, Kazuo Nakamura. (2010) Pleiotropic Effects of Dietary Fatty Acids and Fatty Acid Involvement in Chronic Mild Inflammation-related Diseases. JOURNAL OF HEALTH SCIENCE 56:5, 473-487
CrossRef117
Wonjae Lee, Jung-Won Suh, Han-Mo Yang, Dong-A Kwon, Hyun-Ju Cho, Hyun-Jae Kang, Hyo-Soo Kim, Byung-Hee Oh. (2010) Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers. Korean Circulation Journal 40:7, 321
CrossRef118
Peter R. Holt, Peter Kozuch, Seetal Mewar. (2009) Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly. Best Practice & Research Clinical Gastroenterology 23:6, 889-907
CrossRef119
B Renner, K Brune. (2009) Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?. Clinical Pharmacology & Therapeutics 86:6, 599-600
CrossRef120
P. Fabbrini, M. N. Schilte, M. Zareie, P. M. ter Wee, E. D. Keuning, R. H. J. Beelen, J. van den Born. (2009) Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrology Dialysis Transplantation 24:12, 3669-3676
CrossRef121
P. Thermann, T. Seufferlein. (2009) Primäre und sekundäre Prävention sporadischer kolorektaler Karzinome. Der Onkologe 15:12, 1193-1205
CrossRef122
Benedict W. Wheeler, Chris Metcalfe, David Gunnell, Peter Stephens, Richard M. Martin. (2009) Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. British Journal of Clinical Pharmacology 68:5, 752-764
CrossRef123
D. A. WATTCHOW, D. DE FONTGALLAND, P. A. BAMPTON, P. L. LEACH, K. MCLAUGHLIN, M. COSTA. (2009) Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery - a randomized double blind controlled trial of celecoxib or diclofenac vs. placebo. Alimentary Pharmacology & Therapeutics 30:10, 987-998
CrossRef124
Tatsuya Kaneshiro, Masae Okumura, Samer Maalouf, Andre Uflacker, Takayuki Maruyama, Toshihiko Kawamori. (2009) Inhibition of prostaglandin E2 signaling through the EP1 receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins & Other Lipid Mediators 90:1-2, 31-36
CrossRef125
Matias E. Valsecchi, Sherry C. Pomerantz, Rebecca Jaslow, William Tester. (2009) Reduced Risk of Bone Metastasis for Patients With Breast Cancer Who Use COX-2 Inhibitors. Clinical Breast Cancer 9:4, 225-230
CrossRef126
Michio Kaneko, Setsuko Kaneko, Kenshi Suzuki. (2009) Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Science 100:11, 2193-2201
CrossRef127
Christianne L. Roumie, Neesha N. Choma, Lisa Kaltenbach, Edward F. Mitchel, Jr, Patrick G. Arbogast, Marie R. Griffin. (2009) Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety 18:11, 1053-1063
CrossRef128
Fei-Yuan Hsiao, Yi-Wen Tsai, Weng-Foung Huang. (2009) Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in Taiwan. Clinical Therapeutics 31:11, 2618-2627
CrossRef129
Annelies Debucquoy, Sarah Roels, Laurence Goethals, Louis Libbrecht, Eric Van Cutsem, Karel Geboes, Freddy Penninckx, André D’Hoore, William H. McBride, Karin Haustermans. (2009) Double blind randomized phase II study with radiation+5-fluorouracil±celecoxib for resectable rectal cancer. Radiotherapy and Oncology 93:2, 273-278
CrossRef130
Imtiaz Malik, Farabi Hussein, David Bush, Munther Alqaisi, Pedro Bernal, Janet Byrd, Carlos Garberoglio. (2009) A Phase I Study of Capecitabine, Irinotecan, Celecoxib, and Radiation as Neoadjuvant Therapy of Patients With Locally Advanced Rectal Cancer. American Journal of Clinical Oncology1
CrossRef131
Christopher J. Hawkey, Lars-Erik Svedberg, Jørgen Næsdal, Claire Byrne. (2009) Esomeprazole for the Management of Upper Gastrointestinal Symptoms in Patients Who Require NSAIDs. Clinical Drug Investigation 29:10, 677-687
CrossRef132
Daniel Iglesias, Nargisse Nejda, Mariano Moreno Azcoita, Simó Schwartz, Juan J. González-Aguilera, Antonia M. Fernández-Peralta. (2009) Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes & Control 20:8, 1421-1429
CrossRef133
C. Pox, S. Schmiegel, K. Schulmann, S. Stemmler, H. Schrader, I.A. Adamietz. (2009) Prävention und Diagnose kolorektaler Karzinome. Der Onkologe 15:10, 1033-1048
CrossRef134
L. STRUTHMANN, N. HELLWIG, J. PIRCHER, H.-Y. SOHN, M. A. BUERKLE, V. KLAUSS, H. MANNELL, U. POHL, F. KRÃTZ. (2009) Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. Journal of Thrombosis and Haemostasis 7:10, 1727-1735
CrossRef135
Rachid Zagani, Nadim Hamzaoui, Wulfran Cacheux, Aurélien de Reyniès, Benoît Terris, Stanislas Chaussade, Béatrice Romagnolo, Christine Perret, Dominique Lamarque. (2009) Cyclooxygenase-2 Inhibitors Down-regulate Osteopontin and Nr4a2—New Therapeutic Targets for Colorectal Cancers. Gastroenterology 137:4, 1358-1366.e3
CrossRef136
J. Boone, R. van Hillegersberg, G. J. A. Offerhaus, P. J. van Diest, I. H. M. Borel Rinkes, F. J. W. ten Kate. (2009) Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Diseases of the Esophagus 22:6, 496-504
CrossRef137
Michael F. Picco, John R. Cangemi. (2009) Inflammatory Bowel Disease in the Elderly. Gastroenterology Clinics of North America 38:3, 447-462
CrossRef138
E. Chilet-Rosell, M. T. Ruiz-Cantero, J. F. Horga. (2009) Women's health and gender-based clinical trials on etoricoxib: methodological gender bias. Journal of Public Health 31:3, 434-445
CrossRef139
RL Jones, MA Giembycz, DF Woodward. (2009) Prostanoid receptor antagonists: development strategies and therapeutic applications. British Journal of Pharmacology 158:1, 104-145
CrossRef140
Kevin J. Ruff, Anne Winkler, Robert W. Jackson, Dale P. DeVore, Barry W. Ritz. (2009) Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study. Clinical Rheumatology 28:8, 907-914
CrossRef141
C. Falandry, M. Debled, T. Bachelot, T. Delozier, J. Crétin, P. Romestaing, D. Mille, B. You, L. Mauriac, E. Pujade-Lauraine, G. Freyer. (2009) Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Research and Treatment 116:3, 501-508
CrossRef142
Y. YU, E. RICCIOTTI, T. GROSSER, G. A. FITZGERALD. (2009) The translational therapeutics of prostaglandin inhibition in atherothrombosis. Journal of Thrombosis and Haemostasis 7, 222-226
CrossRef143
Nadine A. Jackson, José Barrueco, Raoudha Soufi-Mahjoubi, John Marshall, Edith Mitchell, Xiaoxi Zhang, Jeffrey Meyerhardt. (2009) Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer 115:12, 2617-2629
CrossRef144
I Chau, D Cunningham. (2009) Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer 100:11, 1704-1719
CrossRef145
Zeina A. Habib, Leonidas Tzogias, Suzanne L. Havstad, Karen Wells, George Divine, David E. Lanfear, Jeffrey Tang, Richard Krajenta, Manel Pladevall, L. Keoki Williams. (2009) Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiology and Drug Safety 18:6, 437-447
CrossRef146
K. Holte, J. Andersen, D. Hjort Jakobsen, H. Kehlet. (2009) Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery. British Journal of Surgery 96:6, 650-654
CrossRef147
M. Barry, R. A. Cahill, G. Roche-Nagle, T. G. Neilan, A. Treumann, J. H. Harmey, D. J. Bouchier-Hayes. (2009) Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. Irish Journal of Medical Science 178:2, 201-208
CrossRef148
H. Krum, S. P. Curtis, A. Kaur, H. Wang, S. S. Smugar, M. R. Weir, L. Laine, D. C. Brater, C. P. Cannon. (2009) Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. European Journal of Heart Failure 11:6, 542-550
CrossRef149
Andrew T. Chan, Ann G. Zauber, Meier Hsu, Aurora Breazna, David J. Hunter, Rebecca B. Rosenstein, Craig J. Eagle, Ernest T. Hawk, Monica M.. Bertagnolli. (2009) Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 136:7, 2127-2136.e1
CrossRef150
Stephen Daniels, Jeffery Robbins, Christine R. West, Mary Anne Nemeth. (2009) Celecoxib in the treatment of primary dysmenorrhea: Results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clinical Therapeutics 31:6, 1192-1208
CrossRef151
Emilie Pecchi, Michel Dallaporta, André Jean, Sylvie Thirion, Jean-Denis Troadec. (2009) Prostaglandins and sickness behavior: Old story, new insights. Physiology & Behavior 97:3-4, 279-292
CrossRef152
James M. Scheiman. (2009) Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology Clinics of North America 38:2, 305-314
CrossRef153
C.A.C. Hyde, S. Missailidis. (2009) Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. International Immunopharmacology 9:6, 701-715
CrossRef154
Gunnar H Gislason, Peter R Hansen. (2009) NSAIDs in elderly patients with heart failure: stuck between a rock and a hard place?. Aging Health 5:3, 259-262
CrossRef155
D. Wang, V. V. Patel, E. Ricciotti, R. Zhou, M. D. Levin, E. Gao, Z. Yu, V. A. Ferrari, M. M. Lu, J. Xu, H. Zhang, Y. Hui, Y. Cheng, N. Petrenko, Y. Yu, G. A. FitzGerald. (2009) Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proceedings of the National Academy of Sciences 106:18, 7548-7552
CrossRef156
Michael E. Farkouh, Bruce P. Greenberg. (2009) An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs. The American Journal of Cardiology 103:9, 1227-1237
CrossRef157
L. A. GARCÍA RODRÍGUEZ, P. PATRIGNANI, A. GONZÁLEZ-PÉREZ. (2009) Risk of myocardial infarction persisting after discontinuation of non-steroidal anti-inflammatory drugs in the general population. Journal of Thrombosis and Haemostasis 7:5, 892-894
CrossRef158
Robert T. O’Neill. (2009) Medical Product Development, Innovation, and Life-Cycle Regulation: The Challenges for Biostatistics. Statistics in Biosciences 1:1, 1-9
CrossRef159
Marijn Rutgers, Daniël BF Saris, Kiem Gie Auw Yang, Wouter JA Dhert, Laura B Creemers. (2009) Joint injury and osteoarthritis: soluble mediators in the course and treatment of cartilage pathology. Immunotherapy 1:3, 435-445
CrossRef160
Yubin Hao, Tianpei Xie, Alexandru Korotcov, Yanfei Zhou, Xiaowu Pang, Liang Shan, Hongguang Ji, Rajagopalan Sridhar, Paul Wang, Joseph Califano, Xinbin Gu. (2009) Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. International Journal of Cancer 124:9, 2200-2209
CrossRef161
Matthew C. Becker, Thomas H. Wang, Lisa Wisniewski, Kathy Wolski, Peter Libby, Thomas F. Lüscher, Jeffrey S. Borer, Alice M. Mascette, M. Elaine Husni, Daniel H. Solomon, David Y. Graham, Neville D. Yeomans, Henry Krum, Frank Ruschitzka, A. Michael Lincoff, Steven E. Nissen. (2009) Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal 157:4, 606-612
CrossRef162
T.N. de Boer, A.M. Huisman, A.A. Polak, A.G. Niehoff, A.C. van Rinsum, D. Saris, J.W.J. Bijlsma, F.J.P.G. Lafeber, S.C. Mastbergen. (2009) The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment. Osteoarthritis and Cartilage 17:4, 482-488
CrossRef163
James F. Watkins, Matthew S. Mayo, Holly J. Smith, Stephen K. Williamson. (2009) Gemcitabine, irinotecan and celecoxib in patients with biliary cancer. Anti-Cancer Drugs 20:4, 294-300
CrossRef164
Ming-Zhi Zhang, Jie Xu, Bing Yao, Huiyong Yin, Qiuyin Cai, Martha J. Shrubsole, Xiwu Chen, Valentina Kon, Wei Zheng, Ambra Pozzi, Raymond C. Harris. (2009) Inhibition of 11β–hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. Journal of Clinical Investigation 119:4, 876-885
CrossRef165
Carmen M. Navarrete, Bernd L. Fiebich, Amaya García de Vinuesa, Sandra Hess, Antonio C. P. de Oliveira, Eduardo Candelario-Jalil, Francisco J. Caballero, Marco A. Calzado, Eduardo Muñoz. (2009) Opposite effects of anandamide and n -arachidonoyl dopamine in the regulation of prostaglandin E 2 and 8-iso-PGF 2α formation in primary glial cells. Journal of Neurochemistry 109:2, 452-464
CrossRef166
(2009) Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results. Alzheimer's and Dementia 5:2, 93-104
CrossRef167
William N. William, John V. Heymach, Edward S. Kim, Scott M. Lippman. (2009) Molecular targets for cancer chemoprevention. Nature Reviews Drug Discovery 8:3, 213-225
CrossRef168
Jun Zhao, Zhi-jie Wang, Jian-chun Duan, Qing-zhi Guo, Hua Bai, Lu Yang, Tong-tong An, Xin Wang, Yu-yan Wang, Mei-na Wu, Xu-yi Liu, Jie Wang. (2009) A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. Chinese Journal of Cancer Research 21:1, 1-12
CrossRef169
Makoto Mark Taketo, Winfried Edelmann. (2009) Mouse Models of Colon Cancer. Gastroenterology 136:3, 780-798
CrossRef170
Jun Qin, Jianlin Yuan, Ling Li, Heliang Liu, Rongliang Qin, Weijun Qin, Baoqi Chen, He Wang, Kaichun Wu. (2009) In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomedicine & Pharmacotherapy 63:3, 241-248
CrossRef171
M. Chandra, P.J. Kent. (2009) Cyclo-oxygenase-2 Inhibitors and Peripheral Thrombosis – A Case Report Demonstrating a Possible Adverse Effect. EJVES Extra 17:2, 14-16
CrossRef172
Matthias Hermann. (2009) Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Current Rheumatology Reports 11:1, 31-35
CrossRef173
Óscar Lorenzo, Luis M. Blanco-Colio, José L. Martín-Ventura, Eva Sánchez-Galán, Sara Ares-Carrasco, Irene Zubiri, Jesús Egido, José Tuñón. (2009) Nuevos mediadores implicados en la génesis de la aterosclerosis. Clínica e Investigación en Arteriosclerosis 21:1, 25-33
CrossRef174
Lawrence J. Marnett. (2009) The COXIB Experience: A Look in the Rearview Mirror. Annual Review of Pharmacology and Toxicology 49:1, 265-290
CrossRef175
EL Fosbøl, GH Gislason, S Jacobsen, F Folke, ML Hansen, TK Schramm, R Sørensen, JN Rasmussen, SS Andersen, SZ Abildstrom, J Trærup, HE Poulsen, S Rasmussen, L Køber, C Torp-Pedersen. (2009) Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study. Clinical Pharmacology & Therapeutics 85:2, 190-197
CrossRef176
Chumnan Kietpeerakool, Jatupol Srisomboon. (2009) Medical treatment of cervical intraepithelial neoplasia II, III: an update review. International Journal of Clinical Oncology 14:1, 37-42
CrossRef177
Kay Brune, Burkhard Hinz, Ivan Otterness. (2009) Aspirin and acetaminophen: Should they be available over the counter?. Current Rheumatology Reports 11:1, 36-40
CrossRef178
B. Combe, G. Swergold, J. McLay, T. McCarthy, C. Zerbini, P. Emery, L. Connors, A. Kaur, S. Curtis, L. Laine, C. P. Cannon. (2009) Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 48:4, 425-432
CrossRef179
Muhammad A. Munir, Eli Cianciolo, Jun-Ming Zhang. 2009. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND CYCLOOXYGENASE-2 INHIBITORS. , 442-448.
CrossRef180
Natsuko KUSUNOKI, Shinichi KAWAI. (2009) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:1, 29-34
CrossRef181
Anders Sundström, Pär Hallberg. (2009) Data Mining in Pharmacovigilance – Detecting the Unexpected. Drug Safety 32:5, 419-427
CrossRef182
Lee S. Simon. 2009. OSTEOARTHRITIS: ETIOLOGY, PATHOGENESIS, AND TREATMENT. , 241-244.
CrossRef183
Stephan A. Schug, Girish P. Joshi, Frederic Camu, Sharon Pan, Raymond Cheung. (2009) Cardiovascular Safety of the Cyclooxygenase-2 Selective Inhibitors Parecoxib and Valdecoxib in the Postoperative Setting: An Analysis of Integrated Data. Anesthesia & Analgesia 108:1, 299-307
CrossRef184
Vincent Wai-Sun Wong, Francis Ka-Leung Chan. (2009) Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet?. Journal of Gastroenterology 44:S19, 53-56
CrossRef185
Takeo Iwama. (2009) NSAIDs and colorectal cancer prevention. Journal of Gastroenterology 44:S19, 72-76
CrossRef186
Zhihong Yang, Hang Xiao, Huanyu Jin, Phillip T. Koo, Dorothea J. Tsang, Chung S. Yang. (2009) Synergistic actions of atorvastatin with γ-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. International Journal of CancerNA-NA
CrossRef187
Barry Schlansky, Joo Ha Hwang. (2009) Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. Journal of Gastroenterology 44:S19, 44-52
CrossRef188
Tore K. Kvien. 2009. Nonsteroidal Anti-Inflammatory Drugs and Coxibs. , 295-299.
CrossRef189
Jun Haeng Lee, Yong Chan Lee, Seong Woo Jeon, Jeong Wook Kim, Sang Woo Lee, , . (2009) Guidelines of Prevention and Treatment for NSAID-related Peptic Ulcers. The Korean Journal of Gastroenterology 54:5, 309
CrossRef190
Numsen Hail, Reuben Lotan. (2009) Cancer chemoprevention and mitochondria: Targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state. Molecular Nutrition & Food Research 53:1, 49-67
CrossRef191
Kimihiko Yanaoka, Masashi Oka, Noriko Yoshimura, Hisanobu Deguchi, Chizu Mukoubayashi, Shotaro Enomoto, Takao Maekita, Izumi Inoue, Kazuki Ueda, Hirotoshi Utsunomiya, Mikitaka Iguchi, Hideyuki Tamai, Mitsuhiro Fujishiro, Yasushi Nakamura, Tetsuya Tsukamoto, Kenichi Inada, Tatsuya Takeshita, Masao Ichinose. (2009) Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori -negative precancerous lesion. International Journal of CancerNA-NA
CrossRef192
Simona Bancos, Matthew P. Bernard, David J. Topham, Richard P. Phipps. (2009) Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cellular Immunology 258:1, 18-28
CrossRef193
Huahong Xie, Liucun Gao, Na Chai, Jiugang Song, Jun Wang, Zhenshun Song, Caiping Chen, Yanglin Pan, Lina Zhao, Shiren Sun, Kaichun Wu, Mark A. Feitelson, Jie Liu, Daiming Fan. (2009) Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Molecular Carcinogenesis 48:1, 56-65
CrossRef194
Ian L.P. Beales, Olorunseun O. Ogunwobi. (2009) Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. International Journal of CancerNA-NA
CrossRef195
Daniel Brzusek, David Petron. (2008) Treating knee osteoarthritis with intra-articular hyaluronans. Current Medical Research and Opinion 24:12, 3307-3322
CrossRef196
Loren Laine, William B. White, Alaa Rostom, Marc Hochberg. (2008) COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars in Arthritis and Rheumatism 38:3, 165-187
CrossRef197
Sun-Wei Guo. (2008) Emerging drugs for endometriosis. Expert Opinion on Emerging Drugs 13:4, 547-571
CrossRef198
Vladimir R. Babaev, Joshua D. Chew, Lei Ding, Sarah Davis, Matthew D. Breyer, Richard M. Breyer, John A. Oates, Sergio Fazio, MacRae F. Linton. (2008) Macrophage EP4 Deficiency Increases Apoptosis and Suppresses Early Atherosclerosis. Cell Metabolism 8:6, 492-501
CrossRef199
Scott M. Lippman. (2008) The Future of Molecular-Targeted Cancer Chemoprevention. Gastroenterology 135:6, 1834-1841
CrossRef200
Daniela Stoppoloni, Irene Cardillo, Alessandra Verdina, Bruno Vincenzi, Simona Menegozzo, Mario Santini, Ada Sacchi, Alfonso Baldi, Rossella Galati. (2008) Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma. Cancer 113:10, 2761-2769
CrossRef201
Kun Yang, Hongjun Bai, Qi Ouyang, Luhua Lai, Chao Tang. (2008) Finding multiple target optimal intervention in disease-related molecular network. Molecular Systems Biology 4,
CrossRef202
Francis K.L. Chan, Neena S. Abraham, James M. Scheiman, Loren Laine, . (2008) Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal of Gastroenterology 103:11, 2908-2918
CrossRef203
Samir Gupta. (2008) Colorectal Polyps: The Scope and Management of the Problem. The American Journal of the Medical Sciences 336:5, 407-417
CrossRef204
T.-P. van Staa, S. Rietbrock, E. Setakis, H. G. M. Leufkens. (2008) Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. Journal of Internal Medicine 264:5, 481-492
CrossRef205
Brian G. Choi, Gemma Vilahur, M. Urooj Zafar, Luis Cardoso, Daniel Yadegar, Borja Ibanez, James Tunstead, Juan F. Viles-Gonzalez, Mitchell B. Schaffler, Valentin Fuster, Juan J. Badimon. (2008) Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 201:1, 76-84
CrossRef206
László Herszényi, Fabio Farinati, Pál Miheller, Zsolt Tulassay. (2008) Chemoprevention of colorectal cancer: feasibility in everyday practice?. European Journal of Cancer Prevention 17:6, 502-514
CrossRef207
Y. Suh, F. Afaq, J. J. Johnson, H. Mukhtar. (2008) A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF- B-signaling pathways. Carcinogenesis 30:2, 300-307
CrossRef208
Vincent E. Friedewald, Joel S. Bennett, Milton Packer, William C. Roberts, Gary W. Williams. (2008) The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology 102:8, 1046-1055
CrossRef209
Isabelle M. Berquin, Iris J. Edwards, Yong Q. Chen. (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Letters 269:2, 363-377
CrossRef210
Sajani S Lakka, Jasti S Rao. (2008) Antiangiogenic therapy in brain tumors. Expert Review of Neurotherapeutics 8:10, 1457-1473
CrossRef211
John C. Davis, Philip J. Mease. (2008) Insights Into the Pathology and Treatment of Spondyloarthritis: From the Bench to the Clinic. Seminars in Arthritis and Rheumatism 38:2, 83-100
CrossRef212
Daewha Hong, Pamela Flood, Geraldine Diaz. (2008) The Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia. Anesthesia & Analgesia 107:4, 1384-1389
CrossRef213
M. Kay Patterson, Jordi Castellsague, Alexander M. Walker. (2008) Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Pharmacoepidemiology and Drug Safety 17:10, 982-988
CrossRef214
Naveena B. Janakiram, Cooma Indranie, Swamy V. Malisetty, Patlolla Jagan, Vernon E. Steele, Chinthalapally V. Rao. (2008) Chemoprevention of Colon Carcinogenesis by Oleanolic Acid and Its Analog in Male F344 Rats and Modulation of COX-2 and Apoptosis in Human Colon HT-29 Cancer Cells. Pharmaceutical Research 25:9, 2151-2157
CrossRef215
Hang Xiao, Chung S. Yang. (2008) Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention. International Journal of Cancer 123:5, 983-990
CrossRef216
Ajay Goel, Sonia Jhurani, Bharat B. Aggarwal. (2008) Multi-targeted therapy by curcumin: how spicy is it?. Molecular Nutrition & Food Research 52:9, 1010-1030
CrossRef217
Wen-Li Mi, Qi-Liang Mao-Ying, Qiong Liu, Xiao-Wei Wang, Yan-Qing Wang, Gen-Cheng Wu. (2008) Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: Involvement of the cyclooxygenase activity in the spinal cord. Brain Research Bulletin 77:2-3, 98-104
CrossRef218
Henning Bliddal. (2008) Guidelines for the use of nonsurgical interventions in osteoarthritis management. Expert Review of Clinical Immunology 4:5, 583-590
CrossRef219
Suzanne Flier, Wolfgang Buhre, Wolfgang Buhre. (2008) Selective COX-2 inhibitors: New insights into mechanisms of side effects?*. Critical Care Medicine 36:9, 2694-2695
CrossRef220
Anna Tesei, Wainer Zoli, Francesco Fabbri, Carlo Leonetti, Marco Rosetti, Manlio Bolla, Dino Amadori, Rosella Silvestrini. (2008) NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. Nitric Oxide 19:2, 225-236
CrossRef221
D WANG, R DUBOIS. (2008) Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Letters 267:2, 197-203
CrossRef222
Daniel H. Solomon, Robert J. Glynn, Kenneth J. Rothman, Sebastian Schneeweiss, Soko Setoguchi, Helen Mogun, Jerry Avorn, Til Stürmer. (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis & Rheumatism 59:8, 1097-1104
CrossRef223
J T Cross, E M Poole, C M Ulrich. (2008) A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. The Pharmacogenomics Journal 8:4, 237-247
CrossRef224
Emil Loldrup Fosbøl, Gunnar H Gislason, Søren Jacobsen, Steen Z Abildstrom, Morten Lock Hansen, Tina Ken Schramm, Fredrik Folke, Rikke Sørensen, Jeppe N Rasmussen, Lars Køber, Mette Madsen, Christian Torp-Pedersen. (2008) The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiology and Drug Safety 17:8, 822-833
CrossRef225
Gábor Lakatos, László Herszényi, Zsolt Tulassay. (2008) A COX-2-gátlók biztonságossága. Orvosi Hetilap 149:33, 1539-1547
CrossRef226
José W. van der Hoorn, J Wouter Jukema, Marian E. Bekkers, Hans M. Princen, Stefano Corda, Jeff J. Emeis, Paul Steendijk. (2008) Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). Critical Care Medicine1
CrossRef227
Burkhard Hinz, Kay Brune. (2008) Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends in Pharmacological Sciences 29:8, 391-397
CrossRef228
James Todd Auman, Robert Church, Soo-Youn Lee, Mark A. Watson, James W. Fleshman, Howard L. Mcleod. (2008) Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. European Journal of Cancer 44:12, 1754-1760
CrossRef229
Christopher P. Cannon, Cong Chen, Sean P. Curtis, John Viscusi, Tuli Ahmed, Peter M. DiBattiste. (2008) A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives of Drug Information 1:1, 4-13
CrossRef230
R.V. Frolov, M.M. Slaughter, S. Singh. (2008) Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons. Neuroscience 154:4, 1525-1532
CrossRef231
Numsen Hail, Marcela Cortes, Edgar N. Drake, Julian E. Spallholz. (2008) Cancer chemoprevention: A radical perspective. Free Radical Biology and Medicine 45:2, 97-110
CrossRef232
Denis A Poddubnyy, In-Ho Song, Joachim Sieper. (2008) The safety of celecoxib in ankylosing spondylitis treatment. Expert Opinion on Drug Safety 7:4, 401-409
CrossRef233
Ángel Lanas. (2008) Introducción. Gastroenterología y Hepatología 31, 32-33
CrossRef234
Ryuichi Iwakiri, Kazuma Fujimoto. (2008) Roles of NSAIDs and aspirin in bleeding peptic ulcers. Clinical Journal of Gastroenterology 1:2, 33-39
CrossRef235
Carlos Martín de Argila de Prados. (2008) Aproximación A. Evidencias a favor de la prescripción de los inhibidores selectivos de la COX-2. Gastroenterología y Hepatología 31, 34-41
CrossRef236
Roger Jones, Greg Rubin, Francis Berenbaum, James Scheiman. (2008) Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs. The American Journal of Medicine 121:6, 464-474
CrossRef237
Nancy L. Davis, James M. Galliher, Mindy S. Spano, Deborah S. Main, Michael Brannigan, Wilson D. Pace. (2008) Evaluating conflicts of interest in research presented in CME venues. Journal of Continuing Education in the Health Professions 28:4, 220-227
CrossRef238
Christopher M Herndon, Rob W Hutchison, Hildegarde J Berdine, Zachary A Stacy, Judy T Chen, David D Farnsworth, Devra Dang, Joli D Fermo. (2008) Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs. Pharmacotherapy 28:6, 788-805
CrossRef239
T. P. van Staa, L. Smeeth, I. Persson, J. Parkinson, H. G. M. Leufkens. (2008) Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?. Pharmacoepidemiology and Drug Safety 17:5, 475-484
CrossRef240
Susanna M. Proudman, Leslie G. Cleland, Michael J. James. (2008) Dietary Omega-3 Fats for Treatment of Inflammatory Joint Disease: Efficacy and Utility. Rheumatic Disease Clinics of North America 34:2, 469-479
CrossRef241
Larry H Lai, Francis LK Chan. (2008) What is the optimal anti-inflammatory therapy for patients with osteoarthritis and increased cardiovascular risk?. Nature Clinical Practice Gastroenterology & Hepatology 5:5, 240-241
CrossRef242
Elliot V. Hersh, Ramesh Balasubramaniam, Andres Pinto. (2008) Pharmacologic Management of Temporomandibular Disorders. Oral and Maxillofacial Surgery Clinics of North America 20:2, 197-210
CrossRef243
Hang Xiao, Qiang Zhang, Yong Lin, Bandaru S. Reddy, Chung S. Yang. (2008) Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. International Journal of Cancer 122:9, 2115-2124
CrossRef244
Francesco Cipollone, Giancarlo Cicolini, Marco Bucci. (2008) Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives. Pharmacology & Therapeutics 118:2, 161-180
CrossRef245
C. J. Smith, G. A. McKay, M. Fisher. (2008) Diabetes, colorectal cancer and cyclooxygenase 2 inhibition. International Journal of Clinical Practice 62:5, 810-815
CrossRef246
Sjef van der Linden. (2008) Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory Drugs. Wiener Medizinische Wochenschrift 158:7-8, 195-199
CrossRef247
Gurpreet Singh-Ranger, Mohamed Salhab, Kefah Mokbel. (2008) The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Research and Treatment 109:2, 189-198
CrossRef248
Anthony Sebba. (2008) Efficacy and safety of etoricoxib in the treatment of osteoarthritis. Expert Review of Clinical Pharmacology 1:3, 345-355
CrossRef249
Eva Szabo. (2008) Primer: first do no harm—when is it appropriate to plan a cancer prevention clinical trial?. Nature Clinical Practice Oncology
CrossRef250
I. H. Song, D. A. Poddubnyy, M. Rudwaleit, J. Sieper. (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis & Rheumatism 58:4, 929-938
CrossRef251
Anuj Agarwala, William Fisher, Daniel Bruetman, John McClean, David Taber, Michael Titzer, Beth Juliar, Menggang Yu, Tim Breen, Lawrence H. Einhorn, Nasser Hanna. (2008) Gefitinib Plus Celecoxib in Chemotherapy-Na??ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 374-379
CrossRef252
David Tanous, Neil Hime, Roland Stocker. (2008) Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. Redox Report 13:2, 48-59
CrossRef253
Laura E. Targownik, Colleen J. Metge, Stella Leung, Daniel G. Chateau. (2008) The Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs. Gastroenterology 134:4, 937-944.e1
CrossRef254
Tarek A. Hammad, David J. Graham, Judy A. Staffa, Cynthia J. Kornegay, Gerald J. Dal Pan. (2008) Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiology and Drug Safety 17:4, 315-321
CrossRef255
Nadir Arber, Bernard Levin. (2008) Chemoprevention of Colorectal Neoplasia: The Potential for Personalized Medicine. Gastroenterology 134:4, 1224-1237
CrossRef256
Kwok F.J. Ng, Jean-Claude Lawmin, Carina C.F. Li, Suk F. Tsang, Wai M. Tang, Kwong Y. Chiu. (2008) Comprehensive Preoperative Evaluation of Platelet Function in Total Knee Arthroplasty Patients Taking Diclofenac. The Journal of Arthroplasty 23:3, 424-430
CrossRef257
James M. Scheiman. (2008) Prevention of NSAID-induced ulcers. Current Treatment Options in Gastroenterology 11:2, 125-134
CrossRef258
Jay L. Goldstein, James Aisenberg, Salam F. Zakko, Manuela F. Berger, William E. Dodge. (2008) Endoscopic Ulcer Rates in Healthy Subjects Associated with Use of Aspirin (81 mg q.d.) Alone or Coadministered with Celecoxib or Naproxen: A randomized, 1-Week Trial. Digestive Diseases and Sciences 53:3, 647-656
CrossRef259
Mathias B. Forrester. (2008) Impact of withdrawal from market on the pattern of cyclooxygenase-2 inhibitors reported to Texas poison control centers. Toxicological & Environmental Chemistry 90:2, 285-292
CrossRef260
Patrick M. Lynch. (2008) Chemoprevention with special reference to inherited colorectal cancer. Familial Cancer 7:1, 59-64
CrossRef261
Jason D. Burch, Michel Belley, Réjean Fortin, Denis Deschênes, Mario Girard, John Colucci, Julie Farand, Alex G. Therien, Marie-Claude Mathieu, Danielle Denis, Erika Vigneault, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Daigen Xu, Patsy Clark, Steve Rowland, Yongxin Han. (2008) Structure–activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor. Bioorganic & Medicinal Chemistry Letters 18:6, 2048-2054
CrossRef262
Alain Astier. (2008) Pour une stricte qualité des matières premières à usage pharmaceutique. Annales Pharmaceutiques Françaises 66:2, 69-70
CrossRef263
C. Pox, S. Schmiegel. (2008) Vorsorge/Prävention. Der Gastroenterologe 3:2, 100-105
CrossRef264
Aurelio Orjales, Ramón Mosquera, Beatriz López, Roberto Olivera, Luis Labeaga, M. Teresa Núñez. (2008) Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorganic & Medicinal Chemistry 16:5, 2183-2199
CrossRef265
Hee-Jae Kim, Jee-In Chung, Soo Hwan Lee, Yi-Sook Jung, Chang-Hyun Moon, Eun Joo Baik. (2008) Involvement of endogenous prostaglandin F2α on kainic acid-induced seizure activity through FP receptor: The mechanism of proconvulsant effects of COX-2 inhibitors. Brain Research 1193, 153-161
CrossRef266
M.T. Arroyo, S. Mostacero, L. Cortés. (2008) Patología gastroduodenal causada por antiinflamatorios no esteroideos. Medicine - Programa de Formación Médica Continuada Acreditado 10:2, 95-100
CrossRef267
Axel H Schönthal, Thomas C Chen, Florence M Hofman, Stan G Louie, Nicos A Petasis. (2008) Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opinion on Investigational Drugs 17:2, 197-208
CrossRef268
James M Brophy. (2008) Cardiovascular effects of cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine 7:1, 29-36
CrossRef269
Carla R. Scanzello, Neal K. Moskowitz, Allan Gibofsky. (2008) The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Current Rheumatology Reports 10:1, 49-56
CrossRef270
Cliff K. S. Ong, Robin A. Seymour. (2008) An evidence-based update of the use of analgesics in dentistry. Periodontology 2000 46:1, 143-164
CrossRef271
Akio Murase, Takako Okumura, Ayano Sakakibara, Hiroko Tonai-Kachi, Kazunari Nakao, Junji Takada. (2008) Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. European Journal of Pharmacology 580:1-2, 116-121
CrossRef272
Nobuo Nagai, Marc F. Hoylaerts, David J. Gallacher, Hua Rong Lu, H. Roger Lijnen. (2008) Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. Thrombosis Research 122:5, 668-673
CrossRef273
Shigeru Ushiyama, Tomoko Yamada, Yukiko Murakami, Sei-ichiro Kumakura, Shin-ichi Inoue, Keisuke Suzuki, Akira Nakao, Akihiro Kawara, Tomio Kimura. (2008) Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. European Journal of Pharmacology 578:1, 76-86
CrossRef274
Takuro KANEKURA. (2008) Nishi Nihon Hifuka 70:6, 645-650
CrossRef275
Stefan Kaehler, Claudia Marsik, Birgit Heinisch, Christiane Thallinger, Robert Sauermann, Lili Kazemi-Shirazi, Oswald Wagner, Christian Joukhadar. (2008) S-Ibuprofen Effectively Inhibits Thromboxane B<sub>2</sub> Levels and Platelet Function in an Experimental Model of Lipopolysaccharide-Stimulated and Non-Stimulated Whole Blood. Pharmacology 81:2, 181-186
CrossRef276
Suresh Guruswamy, Malisetty V. Swamy, Chang-In Choi, Vernon E. Steele, Chinthalapally V. Rao. (2008) S-adenosylL-methionine inhibits azoxymethane-induced colonic aberrant crypt foci in F344 rats and suppresses human colon cancer Caco-2 cell growth in 3D culture. International Journal of Cancer 122:1, 25-30
CrossRef277
Asokumar Buvanendran, Scott S. Reuben. 2008. Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and COX-2 Inhibitors. , 671-692.
CrossRef278
Robert A. Harrington, Vic Hasselblad, Robert M. Califf. (2008) Defining and Utilizing Surrogates in the Evaluation of Coronary Stents. Journal of the American College of Cardiology 51:1, 33-36
CrossRef279
Scott M. Lippman, J. Jack Lee. 2008. Cancer Chemoprevention. , 711-720.
CrossRef280
Brian A. Williams, Krystof J. Neumann, Shiv K. Goel, Christopher L. Wu. 2008. Postoperative Pain and Other Acute Pain Syndromes. , 299-334.
CrossRef281
Myrthe P. P. Sukel, Michiel W. van der Linden, Connie Chen, Joëlle A. Erkens, Ron M. C. Herings. (2008) Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiology and Drug Safety 17:1, 9-19
CrossRef282
Benton E. Heyworth, Jonathan H. Lee, Paul D. Kim, Carter B. Lipton, Robert J. Strauch, Melvin P. Rosenwasser. (2008) Hylan Versus Corticosteroid Versus Placebo for Treatment of Basal Joint Arthritis: A Prospective, Randomized, Double-Blinded Clinical Trial. The Journal of Hand Surgery 33:1, 40-48
CrossRef283
Curtis L. Meinert, John C.S. Breitner. (2008) Chronic disease long-term drug prevention trials: Lessons from the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer's and Dementia 4:1, S7-S14
CrossRef284
Christopher L. Wu, Spencer S. Liu. 2008. Outcomes, Efficacy, and Complications from Acute Postoperative Pain Management. , 1219-1233.
CrossRef285
Naveena B Janakiram, Chinthalapally V Rao. (2008) Molecular markers and targets for colorectal cancer prevention. Acta Pharmacologica Sinica 29:1, 1-20
CrossRef286
Dingzhi Wang, Raymond N. DuBois. (2008) Peroxisome Proliferator-Activated Receptors and Progression of Colorectal Cancer. PPAR Research 2008, 1-7
CrossRef287
Peter Lance. (2008) Chemoprevention for Colorectal Cancer: Some Progress But a Long Way to Go. Gastroenterology 134:1, 341-343
CrossRef288
Ulric Vinsonneau, Aurore Brondex, Jacques Mansourati, Alain Saraux, Jean Christophe Cornily, Florence Arlès, Patrick Godon, Gilles Quiniou. (2008) Cardiovascular disease in patients with spondyloarthropathies. Joint Bone Spine 75:1, 18-21
CrossRef289
Aishi Kimoto, Akiro Hanaoka, Masao Sasamata, Keiji Miyata. (2008) Pre-clinical and clinical profiles of celecoxib, a new specific cyclooxygenase-2 inhibitor. Folia Pharmacologica Japonica 131:2, 127-136
CrossRef290
Jordi Tauler, James L. Mulshine. (2008) Combination Therapy of PPARγ Ligands and Inhibitors of Arachidonic Acid in Lung Cancer. PPAR Research 2008, 1-7
CrossRef291
Francis KL Chan. (2008) The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment. The American Journal of Gastroenterology 103:1, 221-227
CrossRef292
Leobardo Terán Estrada. (2008) Cardiovascular Risk of Cyclooxigenase Selective Inhibitors. Reumatolog ía Cl ínica (English Edition) 4:3, 107-114
CrossRef293
J. GRAFF, C. SKARKE, U. KLINKHARDT, B. WATZER, S. HARDER, H. SEYBERTH, G. GEISSLINGER, R. M. NÜSING. (2007) Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. Journal of Thrombosis and Haemostasis 5:12, 2376-2385
CrossRef294
Carla R. Scanzello, Neal K. Moskowitz, Allan Gibofsky. (2007) The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Current Pain and Headache Reports 11:6, 415-422
CrossRef295
Samy Suissa, Edeltraut Garbe. (2007) Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nature Clinical Practice Rheumatology 3:12, 725-732
CrossRef296
Vibeke Strand. (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. The Lancet 370:9605, 2138-2151
CrossRef297
Kazunori Yokomine, Tetsuya Nakatsura, Satoru Senju, Naomi Nakagata, Motozumi Minohara, Jun–ichi Kira, Yutaka Motomura, Tatsuko Kubo, Yutaka Sasaki, Yasuharu Nishimura. (2007) Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc Min/+ mice. Cancer Science 98:12, 1930-1935
CrossRef298
Alejandro Escudero-Contreras, Janitzia Vazquez-Mellado Cervantes, Eduardo Collantes-Estevez. (2007) Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatology 2:6, 545-565
CrossRef299
Gayle McKellar, Rajan Madhok, Gurkirpal Singh. (2007) The problem with NSAIDs: What data to believe?. Current Pain and Headache Reports 11:6, 423-427
CrossRef300
William B. White. (2007) Cardiovascular risk, hypertension, and NSAIDs. Current Pain and Headache Reports 11:6, 428-435
CrossRef301
E Selg, C Buccellati, M Andersson, G E Rovati, M Ezinga, A Sala, A-K Larsson, E Ambrosio, L Låstbom, V Capra, B Dahlén, Ryrfeldt, G C Folco, S-E Dahlén. (2007) Antagonism of thromboxane receptors by diclofenac and lumiracoxib. British Journal of Pharmacology 152:8, 1185-1195
CrossRef302
Muhammad A. Munir, Nasr Enany, Jun-Ming Zhang. (2007) Nonopioid Analgesics. Anesthesiology Clinics 25:4, 761-774
CrossRef303
Girish P. Joshi, Ralph Gertler, Ruth Fricker. (2007) Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesthesia & Analgesia 105:6, 1793-1804
CrossRef304
Yan Wu, Sun-Wei Guo. (2007) Suppression of IL-1β-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. European Journal of Obstetrics & Gynecology and Reproductive Biology 135:1, 88-93
CrossRef305
Rei Shibata, Noriyuki Ouchi, Kenneth Walsh, Toyoaki Murohara. (2007) Potential of adiponectin as a cardioprotective agent. Future Cardiology 3:6, 647-656
CrossRef306
Susan S. Jick, James A. Kaye, Hershel Jick. (2007) Diclofenac and acute myocardial infarction in patients with no major risk factors. British Journal of Clinical Pharmacology 64:5, 662-667
CrossRef307
Ana R. Quesada, Miguel Ángel Medina, Emilio Alba. (2007) Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer. BioEssays 29:11, 1159-1168
CrossRef308
Konstantinos Giannitsas, Agelis Konstantinopoulos, Petros Perimenis. (2007) Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data. Expert Opinion on Investigational Drugs 16:11, 1841-1849
CrossRef309
Zeina Nahleh, Azadeh Namakydoust, Rania Bakkar, John Bishop. (2007) Trastuzumab not for ductal carcinoma in situ?. Anti-Cancer Drugs 18:10, 1231-1235
CrossRef310
Andrew Chi, Andrew D Norden, Patrick Y Wen. (2007) Inhibition of angiogenesis and invasion in malignant gliomas. Expert Review of Anticancer Therapy 7:11, 1537-1560
CrossRef311
E. RAHME, H. NEDJAR, A. BIZZI, S. MORIN. (2007) Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Alimentary Pharmacology & Therapeutics 26:10, 1387-1398
CrossRef312
Linda A. Doody, Caroline C. Sigman, Gary J. Kelloff. 2007. Intervention and Chemoprevention of Cancer - Treatment of Carcinogenesis. .
CrossRef313
M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
CrossRef314
Burkhard Hinz, Bertold Renner, Kay Brune. (2007) Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal. Nature Clinical Practice Rheumatology 3:10, 552-560
CrossRef315
Stefano Cascinu, Mario Scartozzi, Giovanna Carbonari, Chiara Pierantoni, Lorena Verdecchia, Cinzia Mariani, Michela Squadroni, Stefania Antognoli, Rosa Rita Silva, Riccardo Giampieri, Rossana Berardi. (2007) COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. American Journal of Clinical Oncology 30:5, 526-530
CrossRef316
Lisa K. Hicks, Andreas Laupacis, Arthur S. Slutsky. (2007) A primer on data safety monitoring boards: mission, methods, and controversies. Intensive Care Medicine 33:10, 1815-1818
CrossRef317
M. Ghosh, H. Wang, Y. Ai, E. Romeo, J. P. Luyendyk, J. M. Peters, N. Mackman, S. K. Dey, T. Hla. (2007) COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR activation. Journal of Experimental Medicine 204:9, 2053-2061
CrossRef318
Alan Matsumoto, Agustin Melian, Arvind Shah, Sean P. Curtis. (2007) Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Current Medical Research and Opinion 23:9, 2259-2268
CrossRef319
Janet van Adelsberg, Peter Gann, Amy T. Ko, Jan-Erik Damber, Christopher Logothetis, Michael Marberger, Bernd J. Schmitz-Drager, Andrea Tubaro, Celia J. Harms, Claus Roehrborn. (2007) The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups*. Current Medical Research and Opinion 23:9, 2063-2070
CrossRef320
Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter E. Smalley, Kathi Hall, Patrick G. Arbogast, Marie R. Griffin. (2007) Risk of Peptic Ulcer Hospitalizations in Users of NSAIDs With Gastroprotective Cotherapy Versus Coxibs. Gastroenterology 133:3, 790-798
CrossRef321
George A. Gale, Kanyawim Kirtikara, Pattama Pittayakhajonwut, Somsak Sivichai, Yodhathai Thebtaranonth, Chawanee Thongpanchang, Vanicha Vichai. (2007) In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis and anti-malarial drugs from Thai flora and microbes. Pharmacology & Therapeutics 115:3, 307-351
CrossRef322
Lisa Bortolotti, Bert Heinrichs. (2007) Delimiting the concept of research: an ethical perspective. Theoretical Medicine and Bioethics 28:3, 157-179
CrossRef323
Jennifer D Holman, Jonathan A Dyer. (2007) Genodermatoses with malignant potential. Current Opinion in Pediatrics 19:4, 446-454
CrossRef324
R.W. Moskowitz, S.B. Abramson, F. Berenbaum, L.S. Simon, M. Hochberg. (2007) Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis and Cartilage 15:8, 849-856
CrossRef325
Katerina Antoniou, Michael Malamas, Alexandros A Drosos. (2007) Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opinion on Pharmacotherapy 8:11, 1719-1732
CrossRef326
Paul J. Desjardins, Peter M. Black, Stephen E. Daniels, Steven R. Bird, Richard A. Petruschke, David J. Chang, Steven S. Smugar, Andrew M. Tershakovec. (2007) A Double-Blind Randomized Controlled Trial of Rofecoxib and Multidose Oxycodone/Acetaminophen in Dental Impaction Pain. Journal of Oral and Maxillofacial Surgery 65:8, 1624-1632
CrossRef327
Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, Justine L., Midgley, Rachel S.J., Stanley, Andrew, Stokes, Joanne C., Julier, Patrick, Iveson, Claire, Duvvuri, Ravi, McConkey, Christopher C., . (2007) Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. New England Journal of Medicine 357:4, 360-369
Full Text328
Elmar Friderichs, Thomas Christoph, Helmut Buschmann. 2007. Analgesics and Antipyretics. .
CrossRef329
Isabelle M. Berquin, Younong Min, Ruping Wu, Jiansheng Wu, Donna Perry, J. Mark Cline, Mike J. Thomas, Todd Thornburg, George Kulik, Adrienne Smith, Iris J. Edwards, Ralph D’Agostino, Hao Zhang, Hong Wu, Jing X. Kang, Yong Q. Chen. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. Journal of Clinical Investigation 117:7, 1866-1875
CrossRef330
R A Madan, Q Xia, V T Chang, R G Oriscello, B Kasimis. (2007) A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Expert Opinion on Pharmacotherapy 8:10, 1425-1431
CrossRef331
Li-Chia Chen, Darren M Ashcroft. (2007) Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials. Pharmacoepidemiology and Drug Safety 16:7, 762-772
CrossRef332
Larissa Feldman, Beny Masella, Hyman Tannenbaum. (2007) A pharmacist's perspective: Proceedings from the Third Canadian Consensus Conference: An Evidence-Based Approach to Prescribing NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis. Canadian Pharmacists Journal 140:4, 244-253
CrossRef333
Gary J. Kelloff, Caroline C. Sigman. (2007) Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development. Nature Reviews Cancer 7:7, 508-518
CrossRef334
Olorunseun Olatunji Ogunwobi, Ian L. P. Beales. (2007) Cyclo-oxygenase-Independent Inhibition of Apoptosis and Stimulation of Proliferation by Leptin in Human Colon Cancer Cells. Digestive Diseases and Sciences 52:8, 1934-1945
CrossRef335
Elin Lindhagen, Linda Rickardson, Gary Elliott, Lorenzo Leoni, Peter Nygren, Rolf Larsson, Anna Åleskog. (2007) Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro. Investigational New Drugs 25:4, 297-303
CrossRef336
Soo-Jeong Cho, Nayoung Kim, Joo Sung Kim, Hyun Chae Jung, In Sung Song. (2007) The Anti-Cancer Effect of COX-2 Inhibitors on Gastric Cancer Cells. Digestive Diseases and Sciences 52:7, 1713-1721
CrossRef337
Gunnar Lindberg. (2007) Resialylation of sialic acid deficit vascular endothelium, circulating cells and macromolecules may counteract the development of atherosclerosis: A hypothesis. Atherosclerosis 192:2, 243-245
CrossRef338
M. Lazzaroni, A. Battocchia, G. Bianchi Porro. (2007) COXIBs and non-selective NSAIDs in the gastroenterological setting: What should patients and physicians do?. Digestive and Liver Disease 39:6, 589-596
CrossRef339
Brian B. Hasinoff, Daywin Patel, Xing Wu. (2007) The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovascular Toxicology 7:1, 19-27
CrossRef340
Julia Metzner, Laura Popp, Claudiu Marian, Ronald Schmidt, Christine Manderscheid, Christoph Renne, Beate Fisslthaler, Ingrid Fleming, Rudi Busse, Gerd Geisslinger, Ellen Niederberger. (2007) The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE−/− mice. Journal of Molecular Medicine 85:6, 623-633
CrossRef341
Fr??d??ric Martin, Dominique Fletcher, Marcel Chauvin, Didier Bouhassira. (2007) Constitutive Cyclooxygenase-2 Is Involved in Central Nociceptive Processes in Humans. Anesthesiology 106:5, 1013-1018
CrossRef342
Elham Rahme, Douglas J. Watson, Sheldon X. Kong, Youssef Toubouti, Jacques LeLorier. (2007) Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiology and Drug Safety 16:5, 493-503
CrossRef343
L.F. Fecker, E. Stockfleth, I. Nindl, C. Ulrich, T. Forschner, J. Eberle. (2007) The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). British Journal of Dermatology 156:s3, 25-33
CrossRef344
Antoni Castells, Francesc Balaguer, Victòria Gonzalo, Sergi Castellví-Bel. (2007) Ciclooxigenasa 2 y cáncer colorrectal: implicaciones terapéuticas. Gastroenterología y Hepatología 30:5, 280-284
CrossRef345
Monica M Bertagnolli. (2007) Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. The Lancet Oncology 8:5, 439-443
CrossRef346
Jaideep Behari, Gang Zeng, Wade Otruba, Michael D. Thompson, Peggy Muller, Amanda Micsenyi, Sandeep S. Sekhon, Lorenzo Leoni, Satdarshan P.S. Monga. (2007) R-Etodolac decreases β-catenin levels along with survival and proliferation of hepatoma cells. Journal of Hepatology 46:5, 849-857
CrossRef347
James M Scheiman, A Mark Fendrick. (2007) Summing the risk of NSAID therapy. The Lancet 369:9573, 1580-1581
CrossRef348
Francis Ka Leung Chan, Vincent Wai Sun Wong, Bing Yee Suen, Justin Che Yuen Wu, Jessica Yuet Ling Ching, Lawrence Cheung Tsui Hung, Aric Josun Hui, Vincent King Sun Leung, Vivian Wing Yan Lee, Larry Hin Lai, Grace Lai Hung Wong, Dorothy Kai Lai Chow, Ka Fa To, Wai Keung Leung, Philip Wai Yan Chiu, Yuk Tong Lee, James Yun Wong Lau, Henry Lik Yuen Chan, Enders Kwok Wai Ng, Joseph Jao Yiu Sung. (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. The Lancet 369:9573, 1621-1626
CrossRef349
Miguel Ángel Medina, Ramón Muñoz-Ch´puli, Ana R. Quesada. (2007) Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. Journal of Cellular and Molecular Medicine 11:3, 374-382
CrossRef350
Andrea Morgner, Stephan Miehlke, Joachim Labenz. (2007) Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opinion on Pharmacotherapy 8:7, 975-988
CrossRef351
E. I. Heath, M. I. Canto, S. Piantadosi, E. Montgomery, W. M. Weinstein, J. G. Herman, A. J. Dannenberg, V. W. Yang, A. O. Shar, E. Hawk, A. A. Forastiere. (2007) Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial. JNCI Journal of the National Cancer Institute 99:7, 545-557
CrossRef352
L M Lichtenberger, J J Romero, E J Dial. (2007) Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. British Journal of Pharmacology 150:7, 913-919
CrossRef353
William B. White. (2007) Cardiovascular risk, hypertension, and NSAIDs. Current Rheumatology Reports 9:1, 36-43
CrossRef354
Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette Wozniak. (2007) Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2:4, 299-305
CrossRef355
Cristina Varas-Lorenzo, Andrew Maguire, Jordi Castellsague, Susana Perez-Gutthann. (2007) Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiology and Drug Safety 16:4, 366-376
CrossRef356
N. S. ABRAHAM, H. B. EL-SERAG, C. HARTMAN, P. RICHARDSON, A. DESWAL. (2007) Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Alimentary Pharmacology & Therapeutics 25:8, 913-924
CrossRef357
Sonia Hernández-Díaz, Luis A. García Rodríguez. (2007) Nonsteroidal anti-inflammatory drugs and risk of lung cancer. International Journal of Cancer 120:7, 1565-1572
CrossRef358
Chiara Cuccurullo, Andrea Mezzetti, Francesco Cipollone. (2007) COX-2 and the vasculature: Angel or evil?. Current Hypertension Reports 9:1, 73-80
CrossRef359
Frédéric Aubrun, Frédéric Marmion. (2007) The elderly patient and postoperative pain treatment. Best Practice & Research Clinical Anaesthesiology 21:1, 109-127
CrossRef360
Carsten Denkert, Andrea Thoma, Silvia Niesporek, Wilko Weichert, Ines Koch, Aurelia Noske, Hanka Schicktanz, Mick Burkhardt, Klaus Jung, Manfred Dietel, Glen Kristiansen. (2007) Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of polo-like kinase-1. The Prostate 67:4, 361-369
CrossRef361
Frank Ruschitzka. (2007) Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension. Current Hypertension Reports 9:1, 41-44
CrossRef362
N L P Barnes, F Warnberg, G Farnie, D White, W Jiang, E Anderson, N J Bundred. (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. British Journal of Cancer 96:4, 575-582
CrossRef363
U. Veronesi, P. Maisonneuve, A. Decensi. (2007) Tamoxifen: An Enduring Star. JNCI Journal of the National Cancer Institute 99:4, 258-260
CrossRef364
Young Ho Lee, Jong Dae Ji, Gwan Gyu Song. (2007) Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatology International 27:5, 477-482
CrossRef365
Patrick M. Lynch. (2007) The role of aspirin in the prevention of polyp recurrence: What is the right dose?. Current Colorectal Cancer Reports 3:1, 24-28
CrossRef366
H.-B. YANG, H.-C. CHENG, B.-S. SHEU, K.-H. HUNG, M.-F. LIOU, J.-J. WU. (2007) Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 25:4, 455-461
CrossRef367
Yong I. Cha, Raymond N. DuBois. (2007) NSAIDs and Cancer Prevention: Targets Downstream of COX-2. Annual Review of Medicine 58:1, 239-252
CrossRef368
Asad Umar, Ellen Richmond, Donna J. Griebel. (2007) Colorectal cancer prevention: Diet, drugs, or nothing. Current Colorectal Cancer Reports 3:1, 16-23
CrossRef369
John A. Cairns. (2007) The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks. Canadian Journal of Cardiology 23:2, 125-131
CrossRef370
Elizabeth Half, Frank A. Sinicrope. (2007) Current status of colorectal cancer chemoprevention. Current Colorectal Cancer Reports 3:1, 39-48
CrossRef371
Scott D Solomon. (2007) Cyclooxygenase-2 inhibitors and cardiovascular risk. Current Opinion in Internal Medicine 6:1, 26-30
CrossRef372
Edward H.C. Wong, Thomas W.H. Leung, K.S. Lawrence Wong. (2007) Stroke Caused by Small Vessel Occlusion in a Patient Taking Etoricoxib and Thalidomide. Journal of Neuroimaging 17:1, 87-88
CrossRef373
R. Sim, D. M. Cheong, K. S. Wong, B. M. K. Lee, Q. Y. Liew. (2007) Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery. Colorectal Disease 9:1, 52-60
CrossRef374
E. Viel, S. Jaber, J. Ripart, F. Navarro, J.-J. Eledjam. (2007) Analgesia postoperatoria nell’adulto (esclusa quella ambulatoriale). EMC - Anestesia-Rianimazione 12:2, 1-26
CrossRef375
Gang Liu, Hongyu Zhao, Bo Liu, Zhili Xin, Mei Liu, Michael D. Serby, Nathan L. Lubbers, Deborah L. Widomski, James S. Polakowski, David W.A. Beno, James M. Trevillyan, Hing L. Sham. (2007) Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: Implication for targeting protein kinases in metabolic diseases. Bioorganic & Medicinal Chemistry Letters 17:2, 495-500
CrossRef376
Elliot V. Hersh, Andres Pinto, Paul A. Moore. (2007) Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clinical Therapeutics 29:11, 2477-2497
CrossRef377
James E Frampton, Gillian M Keating. (2007) Celecoxib. Drugs 67:16, 2433-2472
CrossRef378
Marta L. Capone, Stefania Tacconelli, Luigia Di Francesco, Andrea Sacchetti, Maria G. Sciulli, Paola Patrignani. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & Other Lipid Mediators 82:1-4, 85-94
CrossRef379
Angel Lanas, James Scheiman. (2007) Low-dose aspirin and upper gastrointestinal damage:epidemiology, prevention and treatment. Current Medical Research and Opinion 23:1, 163-173
CrossRef380
Todd A. Lee, Brian Bartle, Kevin B. Weiss. (2007) Impact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans. The American Journal of Medicine 120:1, 98.e9-98.e16
CrossRef381
Franco Dallegri, Luciano Ottonello. (2007) Are there any Differences among Non-Steroidal Anti-Inflammatory Drugs? Focus on Nimesulide. Clinical Drug Investigation 27:Suppl 1, 15???22
CrossRef382
Noori S. Al-Waili, Khelod Y. Saloom, Thia Al-Waili, Ali Al-Waili, Hamza Al-Waili. (2007) Modulation of prostaglandin activity, part 1: Prostaglandin inhibition in the management of nonrheumatologic diseases: Immunologic and hematologic aspects. Advances in Therapy 24:1, 189-222
CrossRef383
Kay Brune, Hanns Ulrich Zeilhofer. 2007. Analgésicos antipiréticos. , 471-482.
CrossRef384
Jules I Schwartz, Paul N.-A Kotey, James R Fricke, Keith Gottesdiener. (2007) MK-0703 (a Cyclooxygenase-2 inhibitor) in Acute Pain Associated with Dental Surgery: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Dose-Ranging Study. American Journal of Therapeutics 14:1, 13-19
CrossRef385
D.J.A. de Groot, E.G.E. de Vries, H.J.M. Groen, S. de Jong. (2007) Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Critical Reviews in Oncology/Hematology 61:1, 52-69
CrossRef386
Carlo C. Maley. (2007) Multistage carcinogenesis in Barrett's esophagus. Cancer Letters 245:1-2, 22-32
CrossRef387
Shingo TSUJI. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:4, 213-218
CrossRef388
Meetha Medhora, Anuradha Dhanasekaran, Stephanie K. Gruenloh, Laurel K. Dunn, Michael Gabrilovich, John R. Falck, David R. Harder, Elizabeth R. Jacobs, Phillip F. Pratt. (2007) Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins & Other Lipid Mediators 82:1-4, 19-29
CrossRef389
Debasish Das, Nadir Arber, Janusz A. Jankowski. (2007) Chemoprevention of Colorectal Cancer. Digestion 76:1, 51-67
CrossRef390
Yutaka Kawahito. (2007) Clinical implications of cyclooxygenase-2 inhibitors. Inflammation and Regeneration 27:6, 552-558
CrossRef391
W.J. Elliott. (2007) Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. Yearbook of Cardiology 2007, 55-57
CrossRef392
William M Spalding, Mathew J Reeves, Andrew Whelton. (2007) Thromboembolic Cardiovascular Risk Among Arthritis Patients Using Cyclooxygenase-2-Selective Inhibitor or Nonselective Cyclooxygenase Inhibitor Nonsteroidal Anti-inflammatory Drugs. American Journal of Therapeutics 14:1, 3-12
CrossRef393
B. Hinz, K. Brune. (2007) Schmerztherapie mit antipyretischen Analgetika. Der Orthopäde 36:1, 23-31
CrossRef394
Patrick M. Lynch. (2007) Prevention of Colorectal Cancer in High-Risk Populations: The Increasing Role for Endoscopy and Chemoprevention in FAP and HNPCC. Digestion 76:1, 68-76
CrossRef395
Ian McConachie. (2007) Lessons in drug development. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 54:1, 76-77
CrossRef396
William B. White, Christine R. West, Jeffrey S. Borer, Philip B. Gorelick, Lisa Lavange, Sharon X. Pan, Ethan Weiner, Kenneth M. Verburg. (2007) Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials. The American Journal of Cardiology 99:1, 91-98
CrossRef397
Suniket V. Fulzele, Abhijit Chatterjee, Madhu Sudhan Shaik, Tanise Jackson, Nkechi Ichite, Mandip Singh. (2007) 15-Deoxy-??12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anti-Cancer Drugs 18:1, 65-78
CrossRef398
Fabrizio Montecucco, Sabine Steffens, François Mach. (2007) The Immune Response Is Involved in Atherosclerotic Plaque Calcification: Could the RANKL/RANK/OPG System Be a Marker of Plaque Instability?. Clinical and Developmental Immunology 2007, 1-8
CrossRef399
Muhammad A. Munir, Nasr Enany, Jun-Ming Zhang. (2007) Nonopioid Analgesics. Medical Clinics of North America 91:1, 97-111
CrossRef400
Ying Yu, Colin D. Funk. (2007) A novel genetic model of selective COX-2 inhibition: Comparison with COX-2 null mice. Prostaglandins & Other Lipid Mediators 82:1-4, 77-84
CrossRef401
Ignatius Gerardo E. Zarraga, Ernst R. Schwarz. (2007) Coxibs and Heart Disease. Journal of the American College of Cardiology 49:1, 1-14
CrossRef402
Jacques E. Chelly, Carl W. Nissen, Anthony J. Rodgers, Steven S. Smugar, Andrew M. Tershakovec. (2007) The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain. Current Medical Research and Opinion 23:1, 195-206
CrossRef403
Luis A. García Rodríguez, Antonio González-Péreza. (2007) Cardiovascular Safety of Non-Steroidal Anti-Inflammatory Drugs. Lights and Shadows. Reumatolog ía Cl ínica (English Edition) 3:3, 95-97
CrossRef404
S. J. Dawson, M. Michael, J. Biagi, K. F. Foo, M. Jefford, S. Y. Ngan, T. Leong, A. Hui, A. D. Milner, R. J. S. Thomas, J. R. Zalcberg. (2006) A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Investigational New Drugs 25:2, 123-129
CrossRef405
M M Taketo. (2006) Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 25:57, 7522-7530
CrossRef406
Ivan P Uray, Powel H Brown. (2006) Prevention of breast cancer: current state of the science and future opportunities. Expert Opinion on Investigational Drugs 15:12, 1583-1600
CrossRef407
George Zogopoulos, Steven Gallinger. (2006) Modifiers of risk in familial adenomatous polyposis. Current Colorectal Cancer Reports 2:4, 185-190
CrossRef408
Nick Barker, Hans Clevers. (2006) Mining the Wnt pathway for cancer therapeutics. Nature Reviews Drug Discovery 5:12, 997-1014
CrossRef409
Félix M. Arellano, Marianne Ulcickas Yood, Charles E Wentworth, Susan A Oliveria, Elena Rivero, Anila Verma, Kenneth J Rothman. (2006) Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety 15:12, 861-872
CrossRef410
L-C. Chen, D. M. Ashcroft. (2006) Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 31:6, 565-576
CrossRef411
Marianne Ulcickas Yood, Emmeline Watkins, Karen Wells, Gena Kucera, Christine Cole Johnson, Eva Lydick. (2006) The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiology and Drug Safety 15:12, 852-860
CrossRef412
William H. Wehrmacher, Harry L. Messmore, Waseem Haque. (2006) Pain, analgesics, and the cardiovascular system. Comprehensive Therapy 32:4, 236-239
CrossRef413
J. Braun, J. Zochling, E. Märker-Hermann, G. Stucki, H. Böhm, M. Rudwaleit, H. Zeidler, J. Sieper. (2006) Empfehlungen für das Management der ankylosierenden Spondylitis gemäß ASAS/EULAR. Zeitschrift für Rheumatologie 65:8, 728-742
CrossRef414
Samy Suissa. (2006) Contribution of pharmacoepidemiological studies to the evaluation of treatment-related adverse events. Joint Bone Spine 73:6, 627-628
CrossRef415
Elizabeth E Half, Nadir Arber. (2006) Chemoprevention of colorectal cancer: two steps forward, one step back?. Future Oncology 2:6, 697-704
CrossRef416
Sean P. Curtis, Amy T. Ko, James A. Bolognese, Paul F. Cavanaugh, Alise S. Reicin. (2006) Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX‐2 selective Inhibitor etoricoxib*. Current Medical Research and Opinion 22:12, 2365-2374
CrossRef417
Xavier Bessa i Caserras. (2006) Prevención, cribado y seguimiento de las neoplasias colorrectales. Gastroenterología y Hepatología 29, 72-76
CrossRef418
Lenard M. Lichtenberger, Yong Zhou, Elizabeth J. Dial, Robert M. Raphael. (2006) NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. Journal of Pharmacy and Pharmacology 58:11, 1421-1428
CrossRef419
PATRICIA O'MALLEY. (2006) The Emerging Cardiovascular Risk Profile for Nonsteroidal Anti-inflammatory Drugs. Clinical Nurse Specialist 20:6, 277-265
CrossRef420
Patrick Thiebaud, Bimal V. Patel, Michael B. Nichol. (2006) Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk. Value in Health 9:6, 361-368
CrossRef421
Raj S. Pruthi, Erik Kouba, Culley C. Carson, Eric M. Wallen. (2006) Cyclooxygenase-2 inhibitors and other NSAIDs in urology: Current peril or future promise?. Urology 68:5, 917-923
CrossRef422
Eva Szabo. (2006) Selecting targets for cancer prevention: where do we go from here?. Nature Reviews Cancer 6:11, 867-874
CrossRef423
John H. Farley, Vu Truong, Elwin Goo, Catherine Uyehara, Christina Belnap, Wilma I. Larsen. (2006) A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecologic Oncology 103:2, 425-430
CrossRef424
Weng-Foung Huang, Fei-Yuan Hsiao, Yu-Wen Wen, Y-Wen Tsai. (2006) Cardiovascular events associated with the use of four nonselective NSAIDs (Etodolac, Nabumetone, Ibuprofen, or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib): A population-based analysis in taiwanese adults. Clinical Therapeutics 28:11, 1827-1836
CrossRef425
R. W. THOMSEN, A. RIIS, S. CHRISTENSEN, J. K. MCLAUGHLIN, H. T. SØRENSEN. (2006) Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. Alimentary Pharmacology and Therapeutics 24:10, 1431-1438
CrossRef426
Sebastian Schneeweiss, Daniel H. Solomon, Philip S. Wang, Jeremy Rassen, M. Alan Brookhart. (2006) Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. Arthritis & Rheumatism 54:11, 3390-3398
CrossRef427
Japie A Louw. (2006) Peptic ulcer disease. Current Opinion in Gastroenterology 22:6, 607-611
CrossRef428
Neal M Davies, Jonathon K Reynolds, Megan R Undeberg, Brian J Gates, Yusuke Ohgami, Karina R Vega-Villa. (2006) Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. Expert Review of Neurotherapeutics 6:11, 1643-1655
CrossRef429
Daniel E. Furst, Dinesh Khanna, Harold E. Paulus. (2006) Cyclooxygenase 2 controversy: Thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology. Arthritis & Rheumatism 55:5, 683-686
CrossRef430
2006. Chronic Low Back Pain. .
CrossRef431
Mark Stafford-Smith. (2006) Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:10, 973-977
CrossRef432
Olga Cheremina, Kay Brune, Burkhard Hinz. (2006) A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. Biomedical Chromatography 20:10, 1033-1037
CrossRef433
Jan Steffel, Alexander Akhmedov, Carine Fähndrich, Frank Ruschitzka, Thomas F. Lüscher, Felix C. Tanner. (2006) Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications 349:2, 597-603
CrossRef434
Sharon Bingham, Paul J. Beswick, David E. Blum, Norman M. Gray, Iain P. Chessell. (2006) The role of the cylooxygenase pathway in nociception and pain. Seminars in Cell & Developmental Biology 17:5, 544-554
CrossRef435
Scott D Solomon. (2006) Is elevated cardiovascular risk a class effect of cyclo-oxygenase 2 inhibitors?. Nature Clinical Practice Cardiovascular Medicine 3:10, 532-533
CrossRef436
Narayanan K. Narayanan, Bhagavathi A. Narayanan, Maarten Bosland, Mark S. Condon, Dominick Nargi. (2006) Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. International Journal of Cancer 119:7, 1586-1598
CrossRef437
Mary B. Goldring. (2006) Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Practice & Research Clinical Rheumatology 20:5, 1003-1025
CrossRef438
Francis KL Chan. (2006) Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nature Clinical Practice Gastroenterology & Hepatology 3:10, 563-573
CrossRef439
Hershel Jick, James A Kaye, Stefan Russmann, Susan S Jick. (2006) Nonsteroidal Antiinflammatory Drugs and Acute Myocardial Infarction in Patients with No Major Risk Factors. Pharmacotherapy 26:10, 1379-1387
CrossRef440
Y M Sung, G He, D H Hwang, S M Fischer. (2006) Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 25:40, 5507-5516
CrossRef441
Xiuli Liu, Audrey J. Lazenby, Gene P. Siegal. (2006) Signal Transduction Cross-talk During Colorectal Tumorigenesis. Advances in Anatomic Pathology 13:5, 270-274
CrossRef442
Choitsu Sakamoto, Kentaro Sugano, Shinichi Ota, Nobuhiro Sakaki, Shin’ichi Takahashi, Yukio Yoshida, Taku Tsukui, Hiroyuki Osawa, Yukihiro Sakurai, Junji Yoshino, Yuji Mizokami, Tetsuya Mine, Tetsuo Arakawa, Hajime Kuwayama, Katsunori Saigenji, Koji Yakabi, Tsutomu Chiba, Tooru Shimosegawa, Jane E. Sheehan, Susana Perez-Gutthann, Takuhiro Yamaguchi, David W. Kaufman, Tsugumichi Sato, Kiyoshi Kubota, Akira Terano. (2006) Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. European Journal of Clinical Pharmacology 62:9, 765-772
CrossRef443
Florian B. Mayr, Bernd Jilma. (2006) Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift 156:17-18, 472-480
CrossRef444
D. Williams, M. Singh, C. Hind. (2006) The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. British Journal of Clinical Pharmacology 62:3, 366-368
CrossRef445
P. A. E. Puolakka, A. I. E. Puura, R. A. Pirhonen, A. U. Ranta, V. Autio, L. Lindgren, M. G. F. Rorarius. (2006) Lack of analgesic effect of parecoxib following laparoscopic cholecystectomy. Acta Anaesthesiologica Scandinavica 50:8, 1027-1032
CrossRef446
J. Tuettenberg, C. Friedel, P. Vajkoczy. (2006) Angiogenesis in malignant glioma—A target for antitumor therapy?. Critical Reviews in Oncology/Hematology 59:3, 181-193
CrossRef447
Suniket V. Fulzele, Abhijit Chatterjee, Madhu Sudhan Shaik, Tanise Jackson, Mandip Singh. (2006) Inhalation Delivery and Anti-tumor Activity of Celecoxib in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Model. Pharmaceutical Research 23:9, 2094-2106
CrossRef448
Melanie Maxwell, Michael Nathanson. (2006) Parecoxib - getting to the heart of the matter. Anaesthesia 61:9, 823-825
CrossRef449
Carsten Denkert, Ines Koch, Nora von Keyserlingk, Aurelia Noske, Silvia Niesporek, Manfred Dietel, Wilko Weichert. (2006) Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Modern Pathology 19:9, 1261-1269
CrossRef450
K. Graf. (2006) Aktuelle Studien zum Einsatz von selektiven und nichtselektiven COX-2-Inhibitoren bei Patienten mit kardiovaskulärem Risiko. Clinical Research in Cardiology Supplements 1:1, 39-42
CrossRef451
Patricia McGettigan, Pearline Han, David Henry. (2006) Cyclooxygenase-2 inhibitors and coronary occlusion – exploring dose–response relationships. British Journal of Clinical Pharmacology 62:3, 358-365
CrossRef452
Elena C. Lascano, Héctor F. Valle, Jorge A. Negroni. (2006) Role of the cyclooxygenase pathway in the protection against postischemic stunning in conscious sheep. Molecular and Cellular Biochemistry 289:1-2, 91-100
CrossRef453
Priscilla Velentgas, William West, Carolyn C. Cannuscio, Douglas J. Watson, Alexander M. Walker. (2006) Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology and Drug Safety 15:9, 641-652
CrossRef454
J. B. Richards, L. Joseph, K. Schwartzman, N. Kreiger, A. Tenenhouse, D. Goltzman, . (2006) The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporosis International 17:9, 1410-1419
CrossRef455
Bertagnolli, Monica M., Eagle, Craig J., Zauber, Ann G., Redston, Mark, Solomon, Scott D., Kim, KyungMann, Tang, Jie, Rosenstein, Rebecca B., Wittes, Janet, Corle, Donald, Hess, Timothy M., Woloj, G. Mabel, Boisserie, FrédéricAnderson, William F., Viner, Jaye L., Bagheri, Donya, Burn, John, Chung, Daniel C., Dewar, Thomas, Foley, T. Raymond, Hoffman, Neville, Macrae, Finlay, Pruitt, Ronald E., Saltzman, John R., Salzberg, Bruce, Sylwestrowicz, Thomas, Gordon, Gary B., Hawk, Ernest T., . (2006) Celecoxib for the Prevention of Sporadic Colorectal Adenomas. New England Journal of Medicine 355:9, 873-884
Full Text456
Arber, Nadir, Eagle, Craig J., Spicak, Julius, Rácz, István, Dite, Petr, Hajer, Jan, Zavoral, Miroslav, Lechuga, Maria J., Gerletti, Paola, Tang, Jie, Rosenstein, Rebecca B., Macdonald, Katie, Bhadra, Pritha, Fowler, Robert, Wittes, Janet, Zauber, Ann G., Solomon, Scott D., Levin, Bernard, . (2006) Celecoxib for the Prevention of Colorectal Adenomatous Polyps. New England Journal of Medicine 355:9, 885-895
Full Text457
Psaty, Bruce M., Potter, John D., . (2006) Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas. New England Journal of Medicine 355:9, 950-952
Full Text458
Samy Suissa, Sasha Bernatsky, Marie Hudson. (2006) Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis & Rheumatism 55:4, 531-536
CrossRef459
Jeffrey D. Greenberg, Clifton O. Bingham, Steven B. Abramson, George Reed, Mitsumasa Kishimoto, Kim Hinkle, Joel Kremer, . (2006) Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis & Rheumatism 55:4, 543-550
CrossRef460
Raed Osman, Philippe L L'Allier, Nader Elgharib, Jean-Claude Tardif. (2006) Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vascular Health and Risk Management 2:3, 221-237
CrossRef461
Stacy P Ardoin, John S Sundy. (2006) Update on nonsteriodal anti-inflammatory drugs. Current Opinion in Internal Medicine 5:4, 372-377
CrossRef462
Eyal Sagiv, Lorenzo Memeo, Adi Karin, Diana Kazanov, Jasmin Jacob–Hirsch, Mahesh Mansukhani, Gidi Rechavi, Hanina Hibshoosh, Nadir Arber. (2006) CD24 Is a New Oncogene, Early at the Multistep Process of Colorectal Cancer Carcinogenesis. Gastroenterology 131:2, 630-639
CrossRef463
Wai K. Leung, Joseph J.Y. Sung. (2006) Chemoprevention of gastric cancer. European Journal of Gastroenterology & Hepatology 18:8, 867-871
CrossRef464
June M. Chan, Angela Feraco, Marc Shuman, Sonia Hernández-Díaz. (2006) The Epidemiology of Prostate Cancer—with a Focus on Nonsteroidal Anti-inflammatory Drugs. Hematology/Oncology Clinics of North America 20:4, 797-809
CrossRef465
Jürgen Drews. (2006) Case histories, magic bullets and the state of drug discovery. Nature Reviews Drug Discovery 5:8, 635-640
CrossRef466
Arin K. Greene, Mark Puder. (2006) Prevention of Intra-abdominal Adhesions Using the Antiangiogenic COX-2 Inhibitor Celecoxib. Annals of Surgery 244:2, 328
CrossRef467
R.M. Langford, V. Mehta. (2006) Selective cyclooxygenase inhibition: its role in pain and anaesthesia. Biomedicine & Pharmacotherapy 60:7, 323-328
CrossRef468
Piet Borgdorff, Geert Jan Tangelder, Walter J. Paulus. (2006) Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation. Journal of the American College of Cardiology 48:4, 817-823
CrossRef469
Robert Gryfe. (2006) Clinical Implications of Our Advancing Knowledge of Colorectal Cancer Genetics: Inherited Syndromes, Prognosis, Prevention, Screening and Therapeutics. Surgical Clinics of North America 86:4, 787-817
CrossRef470
S.-J. Myung, R. M. Rerko, M. Yan, P. Platzer, K. Guda, A. Dotson, E. Lawrence, A. J. Dannenberg, A. K. Lovgren, G. Luo, T. P. Pretlow, R. A. Newman, J. Willis, D. Dawson, S. D. Markowitz. (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proceedings of the National Academy of Sciences 103:32, 12098-12102
CrossRef471
(2006) Adverse Cardiovascular Effects of Rofecoxib. New England Journal of Medicine 355:2, 203-205
Full Text472
Jan C. Becker, Nina Grosser, Christian Waltke, Stephanie Schulz, Kati Erdmann, Wolfram Domschke, Henning Schröder, Thorsten Pohle. (2006) Beyond gastric acid reduction: Proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochemical and Biophysical Research Communications 345:3, 1014-1021
CrossRef473
Angel LANAS, Angel FERRANDEZ. (2006) NSAID-induced gastrointestinal damage: Current clinical management and recommendations for prevention. Chinese Journal of Digestive Diseases 7:3, 127-133
CrossRef474
Masami Suganuma, Miki Kurusu, Kaori Suzuki, Emi Tasaki, Hirota Fujiki. (2006) Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation ofGADD153 gene. International Journal of Cancer 119:1, 33-40
CrossRef475
Sith Sathornsumetee, Jeremy N Rich. (2006) New treatment strategies for malignant gliomas. Expert Review of Anticancer Therapy 6:7, 1087-1104
CrossRef476
Ying Yu, Jinjin Fan, Xin-Sheng Chen, Dairong Wang, Andres J Klein-Szanto, Robert L Campbell, Garret A FitzGerald, Colin D Funk. (2006) Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nature Medicine 12:6, 699-704
CrossRef477
Norbert Müller, Markus J Schwarz. (2006) Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders. Expert Review of Neurotherapeutics 6:7, 1017-1038
CrossRef478
Steven S. Smugar, Thomas J. Schnitzer, Arthur L. Weaver, Bernard R. Rubin, Adam B. Polis, Andrew M. Tershakovec. (2006) Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies*. Current Medical Research and Opinion 22:7, 1353-1367
CrossRef479
Thomas J. Schnitzer. (2006) Update on guidelines for the treatment of chronic musculoskeletal pain. Clinical Rheumatology 25:S1, 22-29
CrossRef480
Göran K. Hansson, Peter Libby. (2006) The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 6:7, 508-519
CrossRef481
Almudena Gómez-Hernández, Jose Luis Martín-Ventura, Eva Sánchez-Galán, Cristina Vidal, Mónica Ortego, Luis Miguel Blanco-Colio, Luis Ortega, José Tuñón, Jesús Egido. (2006) Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB. Atherosclerosis 187:1, 139-149
CrossRef482
Jean-Baptiste Méric, Sylvie Rottey, Ken Olaussen, Jean-Charles Soria, David Khayat, Olivier Rixe, Jean-Philippe Spano. (2006) Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology 59:1, 51-64
CrossRef483
Zachary A Stacy, Paul P Dobesh, Toby C Trujillo. (2006) Cardiovascular Risks of Cyclooxygenase Inhibition. Pharmacotherapy 26:7, 919-938
CrossRef484
Mazen Elyan, Muhammad Asim Khan. (2006) The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis. Current Rheumatology Reports 8:4, 255-259
CrossRef485
Lei Zhao, Tilo Grosser, Susanne Fries, Leena Kadakia, He Wang, Jonathan Zhao, Robert Falotico. (2006) Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease. Expert Review of Clinical Immunology 2:4, 649-658
CrossRef486
S. Grosch, T. J. Maier, S. Schiffmann, G. Geisslinger. (2006) Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI Journal of the National Cancer Institute 98:11, 736-747
CrossRef487
Charles J. Gomer, Angela Ferrario, Marian Luna, Natalie Rucker, Sam Wong. (2006) Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment. Lasers in Surgery and Medicine 38:5, 516-521
CrossRef488
C. J. Hawkey, G. M. Hawkey, S. Everitt, M. M. Skelly, W. A. Stack, D. Gray. (2006) Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 61:6, 730-737
CrossRef489
Dustin D. French, Andrea Spehar, Robert Campbell, Thomas N. Chirikos, Tatjana Bulat, Dmitry Vedenov, Stephen L. Luther. (2006) A Medication Surveillance System Model to Improve Patient Safety. Journal of Patient Safety 2:2, 78-82
CrossRef490
Nurullah Akkoc, Sjef van der Linden, Muhammad Asim Khan. (2006) Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Practice & Research Clinical Rheumatology 20:3, 539-557
CrossRef491
Edward H. Lin, Steven A. Curley, Christopher C. Crane, Barry Feig, John Skibber, Marc Delcos, Saroj-Raj Vadhan, Jeffrey Morris, Gregory D. Ayers, Alicia Ross, Thomas Brown, Miguel A. Rodriguez-Bigas, Nora Janjan. (2006) Retrospective Study of Capecitabine and Celecoxib In Metastatic Colorectal Cancer. American Journal of Clinical Oncology 29:3, 232-239
CrossRef492
Bhupesh Parashar, Bridget Shafit-Zagardo. (2006) Inhibition of human Neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor Nimesulide. Journal of Neuro-Oncology 78:2, 129-134
CrossRef493
Mohit Kapoor, Fumiaki Kojima, Leslie J Crofford. (2006) Arachidonic acid-derived eicosanoids in rheumatoid arthritis: implications and future targets. Future Rheumatology 1:3, 323-330
CrossRef494
Evan F. Ekman, Mona Wahba, Frank Ancona. (2006) Analgesic Efficacy of Perioperative Celecoxib in Ambulatory Arthroscopic Knee Surgery: A Double-Blind, Placebo-Controlled Study. Arthroscopy: The Journal of Arthroscopic & Related Surgery 22:6, 635-642
CrossRef495
S. Moncada. (2006) Adventures in vascular biology: a tale of two mediators. Philosophical Transactions of the Royal Society B: Biological Sciences 361:1469, 735-759
CrossRef496
Jane Zochling, Jürgen Braun. (2006) Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. Expert Opinion on Pharmacotherapy 7:7, 869-883
CrossRef497
Thomas M. MacDonald. (2006) A European??s Perspective of COX-2 Drug Safety. Journal of Cardiovascular Pharmacology 47:Supplement 1, S92-S97
CrossRef498
Vibeke Strand. (2006) Expectations From Patients With Rheumatoid Arthritis Regarding COX-2s: Cutting to the Heart of the Matter. Journal of Cardiovascular Pharmacology 47:Supplement 1, S55-S59
CrossRef499
S. K. MURTHY, S. KAULDHER, L. E. TARGOWNIK. (2006) Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. Alimentary Pharmacology and Therapeutics 23:9, 1365-1372
CrossRef500
Aarati Ranganathan, G. Kesava Reddy, Tariq Mughal, Carlos Becerra. (2006) Highlights from: 97th Annual Meeting of the American Association for Cancer Research; Washington, DC; April 2006. Clinical Colorectal Cancer 6:1, 21-24
CrossRef501
Dana Yona, Nadir Arber. (2006) Coxibs and Cancer Prevention. Journal of Cardiovascular Pharmacology 47:Supplement 1, S76-S81
CrossRef502
Tobias Hahn, Irene Alvarez, James J. Kobie, Lalitha Ramanathapuram, Sharon Dial, Amy Fulton, David Besselsen, Edwin Walker, Emmanuel T. Akporiaye. (2006) Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. International Journal of Cancer 118:9, 2220-2231
CrossRef503
Daniel H. Solomon, Jerry Avorn, Til Stürmer, Robert J. Glynn, Helen Mogun, Sebastian Schneeweiss. (2006) Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis & Rheumatism 54:5, 1378-1389
CrossRef504
Francesco Cipollone, Maria Luigia Fazia. (2006) COX-2 and Atherosclerosis. Journal of Cardiovascular Pharmacology 47:Supplement 1, S26-S36
CrossRef505
George Nuki. (2006) Treatment of Crystal Arthropathy—History and Advances. Rheumatic Disease Clinics of North America 32:2, 333-357
CrossRef506
Loren Laine. (2006) GI Risk and Risk Factors of NSAIDs. Journal of Cardiovascular Pharmacology 47:Supplement 1, S60-S66
CrossRef507
Jeffrey S. Borer. (2006) Cyclooxygenase Inhibition: What Should We Do to Resolve the Confusion? An American Perspective. Journal of Cardiovascular Pharmacology 47:Supplement 1, S87-S91
CrossRef508
Francesco Cipollone, Maria Luigia Fazia. (2006) Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk. Current Atherosclerosis Reports 8:3, 245-251
CrossRef509
Mischel G. Neill, Neil E. Fleshner. (2006) An update on chemoprevention strategies in prostate cancer for 2006. Current Opinion in Urology 16:3, 132-137
CrossRef510
Jan Steffel, Thomas F. L??scher, Frank Ruschitzka, Felix C. Tanner. (2006) Cyclooxygenase-2 Inhibition and Coagulation. Journal of Cardiovascular Pharmacology 47:Supplement 1, S15-S20
CrossRef511
José A. Páramo, Óscar Beloqui, Josune Orbe. (2006) Ciclooxigenasa 2: ¿una nueva diana terapéutica en la aterosclerosis?. Medicina Clínica 126:20, 782-786
CrossRef512
C. Kneitz, H. P. Tony, K. Krüger. (2006) NSAR und Coxibe: aktueller Stand. Der Internist 47:5, 533-540
CrossRef513
J. L. GOLDSTEIN, S. C. LOWRY, F. L. LANZA, H. I. SCHWARTZ, W. E. DODGE. (2006) The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Alimentary Pharmacology and Therapeutics 23:10, 1489-1498
CrossRef514
Makoto Mark Taketo. (2006) Mouse models of gastrointestinal tumors. Cancer Science 97:5, 355-361
CrossRef515
M Scott Hogenmiller, Carlos J Lozada. (2006) An update on osteoarthritis therapeutics. Current Opinion in Rheumatology 18:3, 256-260
CrossRef516
Ellen Niederberger, Christine Manderscheid, Gerd Geisslinger. (2006) Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochemical and Biophysical Research Communications 342:3, 940-948
CrossRef517
Axel H. Schönthal. (2006) Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurgical FOCUS 20:4, E21
CrossRef518
Irmgard Tegeder, Gerd Geisslinger. (2006) Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?. Naunyn-Schmiedeberg's Archives of Pharmacology 373:1, 1-17
CrossRef519
Adnan R. Munkarah, Rouba Ali-Fehmi. (2006) Reply. American Journal of Obstetrics and Gynecology 194:4, 1203-1204
CrossRef520
Angel Lanas. (2006) Prevention and treatment of NSAID-induced gastroduodenal injury. Current Treatment Options in Gastroenterology 9:2, 147-156
CrossRef521
Raymond S. Sinatra, Judith A. Boice, Tom L. Loeys, Amy T. Ko, Maureen M. Kashuba, Jonathan S. Jahr, Steven Rhondeau, Neil Singla, Paul F. Cavanaugh, Alise S. Reicin. (2006) Evaluation of the Effect of Perioperative Rofecoxib Treatment on Pain Control and Clinical Outcomes in Patients Recovering From Gynecologic Abdominal Surgery. Regional Anesthesia and Pain Medicine 31:2, 134-142
CrossRef522
Angel Ferrández, Angel Lanas. (2006) The role of COX-2 in chemoprevention of colorectal cancer: A friend or an enemy?. Current Colorectal Cancer Reports 2:1, 5-12
CrossRef523
Fumiaki Kojima, Mohit Kapoor, Shinichi Kawai, Leslie J Crofford. (2006) New insights into eicosanoid biosynthetic pathways: implications for arthritis. Expert Review of Clinical Immunology 2:2, 277-291
CrossRef524
Christopher J. Mehallo, Jonathan A. Drezner, Jeffrey R. Bytomski. (2006) Practical Management: Nonsteroidal Antiinflammatory Drug (NSAID) Use in Athletic Injuries. Clinical Journal of Sport Medicine 16:2, 170-174
CrossRef525
Sonia Hernandez-Diaz, Cristina Varas-Lorenzo, Luis A. Garcia Rodriguez. (2006) Non-Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 266-274
CrossRef526
Nancy A. Nussmeier, Andrew A. Whelton, Mark T. Brown, Girish P. Joshi, Richard M. Langford, Neil K. Singla, Mark E. Boye, Kenneth M. Verburg. (2006) Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery. Anesthesiology 104:3, 518-526
CrossRef527
Michael J James, Leslie G Cleland. (2006) Cyclooxygenase-2 inhibitors: what went wrong?. Current Opinion in Clinical Nutrition and Metabolic Care 9:2, 89-94
CrossRef528
Brian I. Rini, Vivian Weinberg, Sarah Dunlap, Alexandra Elchinoff, Nancy Yu, Robert Bok, Jeffery Simko, Eric J. Small. (2006) Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106:3, 566-575
CrossRef529
Arthur L. Weaver, Ronald P. Messner, William W. Storms, Adam B. Polis, Daryl K. Najarian, Richard A. Petruschke, Gregory P. Geba, Andrew M. Tershakovec. (2006) Treatment of Patients With Osteoarthritis With Rofecoxib Compared With Nabumetone. JCR: Journal of Clinical Rheumatology 12:1, 17-25
CrossRef530
Silvano Adami. (2006) Anti-inflammatory therapy and cardiovascular risk: new insights. Future Rheumatology 1:1, 7-10
CrossRef531
Christopher J Hawkey, Paul J Fortun. (2006) Cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine 5:1, 106-110
CrossRef532
Polymnia Galiatsatos, William D. Foulkes. (2006) Familial Adenomatous Polyposis. The American Journal of Gastroenterology 101:2, 385-398
CrossRef533
Cornelia M. Ulrich, Jeannette Bigler, John D. Potter. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews Cancer 6:2, 130-140
CrossRef534
Alastair J.M. Watson. (2006) An overview of apoptosis and the prevention of colorectal cancer. Critical Reviews in Oncology/Hematology 57:2, 107-121
CrossRef535
Omidreza Firuzi, Domenico Praticò. (2006) Coxibs and Alzheimer's disease: Should they stay or should they go?. Annals of Neurology 59:2, 219-228
CrossRef536
John J. V. McMurray. (2006) Drug Safety in Cardiovascular Disease: A Call to ACTION. Cardiovascular Drugs and Therapy 20:1, 9-10
CrossRef537
Ðngel Lanas, Carmelo Scarpignato. (2006) Microbial Flora in NSAID-Induced Intestinal Damage: A Role for Antibiotics?. Digestion 73:1, 136-150
CrossRef538
Weng-Foung Huang, Fei-Yuan Hsiao, Yi-Wen Tsai, Yu-Wen Wen, Yaw-Tang Shih. (2006) Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan. Drug Safety 29:3, 261-272
CrossRef539
Anthony Barnett. (2006) Using Recovery Modalities between Training Sessions in Elite Athletes. Sports Medicine 36:9, 781-796
CrossRef540
Shin Chung. (2006) Injectable COX-2 inhibitor for postoperative pains. Expert Opinion on Therapeutic Patents 16:1, 95-98
CrossRef541
Jane A. Mitchell, Timothy D. Warner. (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery 5:1, 75-86
CrossRef542
O. H. NIELSEN, M. AINSWORTH, C. CSILLAG, J. RASK-MADSEN. (2006) Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. Alimentary Pharmacology and Therapeutics 23:1, 27-33
CrossRef543
J??rgen N??sdal, Kurt Brown. (2006) NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them. Drug Safety 29:2, 119-132
CrossRef544
Gim Gee Teng, Raj Nair, Kenneth G Saag. (2006) Pathophysiology, Clinical Presentation and Treatment of Gout. Drugs 66:12, 1547-1563
CrossRef545
C. Birbara, G. Ruoff, E. Sheldon, C. Valenzuela, A. Rodgers, R. A. Petruschke, D. J. Chang, A. M. Tershakovec. (2006) Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current Medical Research and Opinion 22:1, 199-210
CrossRef546
Christos Tsatsanis, Ariadne Androulidaki, Maria Venihaki, Andrew N. Margioris. (2006) Signalling networks regulating cyclooxygenase-2. The International Journal of Biochemistry & Cell Biology 38:10, 1654-1661
CrossRef547
Marc Maillard, Michel Burnier. (2006) Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opinion on Drug Safety 5:1, 83-94
CrossRef548
Giampietro Gasparini, Raffaele Longo, Francesco Torino, Domenico Gattuso, Alessandro Morabito, Giuseppe Toffoli. (2006) Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology 57:1, 79-101
CrossRef549
T. Horiguchi, J.A. Snipes, B. Kis, K. Shimizu, D.W. Busija. (2006) Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats. Neuroscience 140:2, 723-730
CrossRef550
Lars Sl??rdal, Olav Spigset. (2006) Heart Failure Induced by Non-Cardiac Drugs. Drug Safety 29:7, 567-586
CrossRef551
Baruch Shpitz, Nis Giladi, Eyal Sagiv, Shahar Lev-Ari, Eliezer Liberman, Diana Kazanov, Nadir Arber. (2006) Celecoxib and Curcumin Additively Inhibit the Growth of Colorectal Cancer in a Rat Model. Digestion 74:3-4, 140-144
CrossRef552
Henry Krum, Frank Ruschitzka. (2006) ‘Class effect’ amongst cardiac drugs: term of convenience or pharmacological reality?. International Journal of Clinical Practice 60:1, 2-5
CrossRef553
Judy T. Chen, Frank Pucino, Beth H. Resman-Targoff. (2006) Celecoxib versus a Non-Selective NSAID Plus Proton-Pump Inhibitor. Journal of Pain and Palliative Care Pharmacotherapy 20:4, 11-32
CrossRef554
Menachem Moshkowitz, Nadir Arber. (2006) Cyclo-Oxygenase-2 Inhibitors in Colorectal Cancer Prevention. American Journal of Cancer 5:6, 357-362
CrossRef555
James M Scheiman. (2006) Unmet Needs in Non-steroidal Anti-inflammatory Drug-induced Upper Gastrointestinal Diseases. Drugs 66:Suppl 1, 15???21
CrossRef556
Burkhard Hinz, Harald Dormann, Kay Brune. (2006) More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis & Rheumatism 54:1, 282-291
CrossRef557
Ramu Raju, Marcia Cruz-Correa. (2006) Chemoprevention of Colorectal Cancer. Diseases of the Colon & Rectum 49:1, 113-125
CrossRef558
Aneta Peric, Marija Toskic-Radojicic. (2006) Analysis of the use and adverse effects of non-steroidal anti-inflammatory drugs: A pilot study. Vojnosanitetski pregled 63:3, 271-277
CrossRef559
Gary W. Williams. (2005) An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Current Pain and Headache Reports 9:6, 377-389
CrossRef560
C. Zerbini, Z. E. Ozturk, J. Grifka, M. Maini, S. Nilganuwong, R. Morales, M. Hupli, M. Shivaprakash, H. Giezek. (2005) Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4‐week, multinational, randomized, double-blind study. Current Medical Research and Opinion 21:12, 2037-2049
CrossRef561
Alan A. Parsa, Christopher W. M. Soon, Fereydoun Don Parsa. (2005) The Use of Celecoxib for Reduction of Pain After Subpectoral Breast Augmentation. Aesthetic Plastic Surgery 29:6, 441-444
CrossRef562
Marie-France Demierre, Peter D. R. Higgins, Stephen B. Gruber, Ernest Hawk, Scott M. Lippman. (2005) Statins and cancer prevention. Nature Reviews Cancer 5:12, 930-942
CrossRef563
Stacy P Ardoin, Laura E Schanberg. (2005) The management of pediatric systemic lupus erythematosus. Nature Clinical Practice Rheumatology 1:2, 82-92
CrossRef564
Vernon E. Steele, Gary J. Kelloff. (2005) Development of cancer chemopreventive drugs based on mechanistic approaches. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 591:1-2, 16-23
CrossRef565
F. Robles-Agudo, F. Sanz-Segovia, J. González-Polo, M. Beltrán de la Ascensión, J.M. López-Arrieta. (2005) Alivio del dolor como parte de los cuidados al final de la vida. Revista Española de Geriatría y Gerontología 40:6, 357-364
CrossRef566
Mitchell Jay Cohen, William P. Schecter. (2005) Perioperative Pain Control: A Strategy for Management. Surgical Clinics of North America 85:6, 1243-1257
CrossRef567
Neena S Abraham, David Y Graham. (2005) NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opinion on Pharmacotherapy 6:15, 2681-2689
CrossRef568
Samir Gupta, Kenneth McQuaid. (2005) Management of Nonsteroidal, Anti-inflammatory, Drug-Associated Dyspepsia. Gastroenterology 129:5, 1711-1719
CrossRef569
Gregory Choy. (2005) An update on the treatment options for gout and calcium pyrophosphate deposition. Expert Opinion on Pharmacotherapy 6:14, 2443-2453
CrossRef570
James M Brophy. (2005) Celecoxib and cardiovascular risks. Expert Opinion on Drug Safety 4:6, 1005-1015
CrossRef571
Robert J. Kaplan. (2005) Current Status of NonsteroidalAnti-Inflammatory Drugsin Physiatry. American Journal of Physical Medicine & Rehabilitation 84:11, 885-894
CrossRef572
Leah M. Backhus, Nicos A. Petasis, Jasim Uddin, Axel H. Schönthal, Robert D. Bart, Yuanguang Lin, Vaughn A. Starnes, Ross M. Bremner. (2005) Dimethyl celecoxib as a novel non–cyclooxygenase 2 therapy in the treatment of non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 130:5, 1406-1412
CrossRef573
Giampietro Gasparini, Raffaele Longo, Masakazu Toi, Napoleone Ferrara. (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice Oncology 2:11, 562-577
CrossRef574
Danny Liew, Henry Krum. (2005) The cardiovascular safety of celecoxib. Future Cardiology 1:6, 709-722
CrossRef575
D E Brenner, A J Gescher. (2005) Cancer chemoprevention: lessons learned and future directions. British Journal of Cancer 93:7, 735-739
CrossRef576
N. L. P. Barnes, N. J. Bundred. (2005) COX-2 inhibitors in breast cancer. Breast Cancer Online 8:10,
CrossRef577
Michael B Sporn, Karen T Liby. (2005) Cancer chemoprevention: scientific promise, clinical uncertainty. Nature Clinical Practice Oncology 2:10, 518-525
CrossRef578
Harlan M. Krumholz. (2005) The Year in Epidemiology, Health Services, and Outcomes Research. Journal of the American College of Cardiology 46:7, 1362-1370
CrossRef579
Frank Ruschitzka. (2005) Are selective cyclo-oxygenase 2 inhibitors safe after coronary artery bypass grafting surgery?. Nature Clinical Practice Cardiovascular Medicine 2:10, 504-505
CrossRef580
E. Beubler. (2005) Klinische Pharmakologie der Schmerzmittel. Der Internist 46:10, 1076-1086
CrossRef581
J Sudbø, JJ Lee, SM Lippman, J Mork, S Sagen, N Flatner, A Ristimäki, A Sudbø, L Mao, X Zhou, W Kildal, JF Evensen, A Reith, AJ Dannenberg. (2005) RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. The Lancet 366:9494, 1359-1366
CrossRef582
Gregory E. Simon, Bruce M. Psaty, Jennifer Berg Hrachovec, Marc Mora. (2005) Principles For Evidence-Based Drug Formulary Policy. Journal of General Internal Medicine 20:10, 964-968
CrossRef583
LUUK B HILBRANDS, FRANS T HUYSMANS, JACK F WETZELS. (2005) Screening for microalbuminuria. Kidney International 68:4, 1899-1900
CrossRef584
A. Brack, H. L. Rittner, M. Schäfer. (2005) Kritische Neubewertung von Zyklooxygenase-2-Inhibitoren in der perioperativen Schmerztherapie. Der Anaesthesist 54:10, 1032-1038
CrossRef585
Rei Shibata, Kaori Sato, David R Pimentel, Yukihiro Takemura, Shinji Kihara, Koji Ohashi, Tohru Funahashi, Noriyuki Ouchi, Kenneth Walsh. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms. Nature Medicine 11:10, 1096-1103
CrossRef586
Lisa K. Stamp, Michael J. James, Leslie G. Cleland. (2005) Diet and Rheumatoid Arthritis: A Review of the Literature. Seminars in Arthritis and Rheumatism 35:2, 77-94
CrossRef587
S. Lev-Ari, H. Zinger, D. Kazanov, D. Yona, R. Ben-Yosef, A. Starr, A. Figer, N. Arber. (2005) Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomedicine & Pharmacotherapy 59, S276-S280
CrossRef588
Michael Karin, Florian R. Greten. (2005) NF-κB: linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 5:10, 749-759
CrossRef589
Werner Kiefer, Gerd Dannhardt. (2005) COX-2 inhibition and pain management: a review summary. Expert Review of Clinical Immunology 1:3, 431-442
CrossRef590
J. BONNET. (2005) Review article: a cardiologist's view of the risks and benefits of cyclo-oxygenase-2 inhibitors, aspirin and other non-steroidal anti-inflammatory drugs. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 11-15
CrossRef591
F. BERENBAUM. (2005) Review article: clinical management of non-steroidal anti-inflammatory drug and cyclo-oxygenase-2 inhibitor users: a European perspective. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 6-10
CrossRef592
(2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:9, i-xii
CrossRef593
Charles N. Serhan. (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes and Essential Fatty Acids 73:3-4, 141-162
CrossRef594
J.J. Grau de Castro. (2005) Inhibidores de la ciclooxigenasa-2 en la prevención del cáncer. Revista Clínica Española 205:9, 446-456
CrossRef595
Andrew T Chan, Charles S Fuchs. (2005) Do cyclo-oxygenase 2 inhibitors increase the risk of cardiovascular events?. Nature Clinical Practice Oncology 2:9, 434-435
CrossRef596
J. M. SCHEIMAN, B. CRYER, M. ASAKA, F. BERENBAUM, J. BONNET, F. K.-L. CHAN, G. KREJS, A. LANAS, A. WEAVER, F. ZERBIB. (2005) Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 26-32
CrossRef597
Hirohito Magari, Yasuhito Shimizu, Ken-ichi Inada, Shotaro Enomoto, Tatsuji Tomeki, Kimihiko Yanaoka, Hideyuki Tamai, Kenji Arii, Hiroya Nakata, Masashi Oka, Hirotoshi Utsunomiya, Yutaka Tsutsumi, Tetsuya Tsukamoto, Masae Tatematsu, Masao Ichinose. (2005) Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Biochemical and Biophysical Research Communications 334:2, 606-612
CrossRef598
Cheng LUO, Ming-liang HE, Lars BOHLIN. (2005) Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial1. Acta Pharmacologica Sinica 26:8, 926-933
CrossRef599
D. PEREG, M. LISHNER. (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. Journal of Internal Medicine 258:2, 115-123
CrossRef600
Marta L Capone, Stefania Tacconelli, Paola Patrignani. (2005) Clinical pharmacology of etoricoxib. Expert Opinion on Drug Metabolism & Toxicology 1:2, 269-282
CrossRef601
Matthew Wagner, James Loos, Nicole Weksler, Marin Gantner, Christopher L. Corless, John M. Barry, Tomasz M. Beer, Mark Garzotto. (2005) Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications 332:3, 800-807
CrossRef602
Daniel H. Solomon. (2005) Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis & Rheumatism 52:7, 1968-1978
CrossRef603
(2005) Cardiovascular Risk Associated with Celecoxib. New England Journal of Medicine 352:25, 2648-2650
Full Text604
Maureen P. Flattery, Leigh Anne Hylton Gravatt. (2005) COX-2 Inhibitors and Cardiovascular Risk. Progress in Cardiovascular Nursing 20:3, 123-125
CrossRef605
Fiona Blackhall, Pavlos I Papakotoulas, Sarah Danson, Nicholas Thatcher. (2005) Perspectives on novel therapies for bronchial carcinoma. Expert Opinion on Pharmacotherapy 6:7, 1157-1167
CrossRef606
Kenneth Khamly, Michael Jefford, Michael Michael, John Zalcberg. (2005) Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opinion on Investigational Drugs 14:6, 607-628
CrossRef607
Gary Spektor, Valentin Fuster. (2005) Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?. Nature Clinical Practice Cardiovascular Medicine 2:6, 290-300
CrossRef608
Carragee, Eugene J., . (2005) Persistent Low Back Pain. New England Journal of Medicine 352:18, 1891-1898
Full Text609
Raban V Jeger, Jeffrey D Greenberg, Krishnan Ramanathan, Michael E Farkouh. (2005) Lumiracoxib, a highly selective COX-2 inhibitor. Expert Review of Clinical Immunology 1:1, 37-45
CrossRef610
Richard Goldberg, Peter Kirkpatrick. (2005) Cetuximab. Nature Reviews Drug Discovery 4:5, S10-S11
CrossRef611
Dena R. Ramey, Douglas J. Watson, Chang Yu, James A. Bolognese, Sean P. Curtis, Alise S. Reicin. (2005) The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis* * Some of the material included in this manuscript was presented at the American College of Rheumatology 2003 Annual Meeting (Orlando, FL, 23–26 November 2003) and at the 2004 European League Against Rheumatism meeting (Berlin, Germany, 9–12 June 2004). Current Medical Research and Opinion 21:5, 715-722
CrossRef612
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef613
Jason R Mann, Michael G Backlund, Raymond N DuBois. (2005) Mechanisms of Disease: inflammatory mediators and cancer prevention. Nature Clinical Practice Oncology 2:4, 202-210
CrossRef614
Okie, Susan, . (2005) Raising the Safety Bar — The FDA's Coxib Meeting. New England Journal of Medicine 352:13, 1283-1285
Full Text615
Psaty, Bruce M., Furberg, Curt D., . (2005) COX-2 Inhibitors — Lessons in Drug Safety. New England Journal of Medicine 352:11, 1133-1135
Full Text616
Drazen, Jeffrey M., . (2005) COX-2 Inhibitors — A Lesson in Unexpected Problems. New England Journal of Medicine 352:11, 1131-1132
Full Text617
Bresalier, Robert S., Sandler, Robert S., Quan, Hui, Bolognese, James A., Oxenius, Bettina, Horgan, Kevin, Lines, Christopher, Riddell, Robert, Morton, Dion, Lanas, Angel, Konstam, Marvin A., Baron, John A., . (2005) Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. New England Journal of Medicine 352:11, 1092-1102
Full Text618
Nussmeier, Nancy A., Whelton, Andrew A., Brown, Mark T., Langford, Richard M., Hoeft, Andreas, Parlow, Joel L., Boyce, Steven W., Verburg, Kenneth M., . (2005) Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. New England Journal of Medicine 352:11, 1081-1091
Full Text619
Ken Shinmura. (2005) Possible mechanisms of cyclooxygenase (COX)-2 hazard: Is COX-2 in the cardiovascular system a friend or a foe?. Ensho Saisei 25:6, 517-524
CrossRef620
Lisa Stamp, Martin Searle, John O???Donnell, Peter Chapman. (2005) Gout in Solid Organ Transplantation. Drugs 65:18, 2593-2611
CrossRef621
Scott A Paluska. (2005) An Overview of Hip Injuries in Running. Sports Medicine 35:11, 991-1014
CrossRef622
Elizabeth J. Westgate, Garret A. FitzGerald. (2005) Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib. PLoS Medicine 2:7, e197
CrossRef623
Mira Harrison-Woolrych, Peter Herbison, Rachael McLean, Janelle Ashton, Jim Slattery. (2005) Incidence of Thrombotic Cardiovascular Events in Patients Taking Celecoxib Compared with Those Taking Rofecoxib. Drug Safety 28:5, 435-442
CrossRef624
Florian Krötz, Thomas M. Schiele, Volker Klauss, Hae-Young Sohn. (2005) Selective COX-2 Inhibitors and Risk of Myocardial Infarction. Journal of Vascular Research 42:4, 312-324
CrossRef625
Maartje Los, Emile E. Voest, Inne H.M. Borel Rinkes. (2005) VEGF as a Target of Therapy in Gastrointestinal Oncology. Digestive Surgery 22:4, 282-293
CrossRef626
Hiltrud Liedgens, Mark J C Nuijten, Barbara Poulsen Nautrup. (2005) Economic Evaluation of Tramadol/Paracetamol Combination Tablets for??Osteoarthritis Pain in The Netherlands. Clinical Drug Investigation 25:12, 785-802
CrossRef627
ROBERT L CHEVALIER. (2004) Promise for gene therapy in obstructive nephropathy. Kidney International 66:4, 1709-1710
CrossRef628
S MIN. (2002) Rheumatology. Medicine 30:8, 1-3
CrossRef629
Christopher J Edwards. (2002) Immune-mediated inflammatory disorders. Medicine 30:8, 1-3
CrossRef
- Letters
